Document:

Note Purchase Agreement

 Exhibit 10(x) 
  
  
  
 SIGMA–ALDRICH CORPORATION 
 $100,000,000 
 7.687% Senior Notes due September 12, 2010 
  
  
 NOTE PURCHASE AGREEMENT 
  
  
 Dated: September 12, 2000

  
  
  

 Exhibit 10(x) (continued) 
  

 TABLE OF CONTENTS 
  

					
	 SECTION
	  	 HEADING
	  	PAGE
	 SECTION 1.
	  	 AUTHORIZATION OF NOTES
	  	1
			
	 SECTION 2.
	  	 SALE AND PURCHASE OF NOTES
	  	1
			
	 SECTION 3.
	  	 CLOSING
	  	2
			
	 SECTION 4.
	  	 CONDITIONS TO CLOSING
	  	2
			
	 Section 4.1.
	  	 Representations and Warranties
	  	2
	 Section 4.2.
	  	 Performance; No Default
	  	2
	 Section 4.3.
	  	 Compliance Certificates
	  	2
	 Section 4.4.
	  	 Opinions of Counsel
	  	3
	 Section 4.5.
	  	 Purchase Permitted by Applicable Law, etc.
	  	3
	 Section 4.6.
	  	 Sale of Other Notes
	  	3
	 Section 4.7.
	  	 Intentionally Deleted
	  	3
	 Section 4.8.
	  	 Private Placement Number
	  	3
	 Section 4.9.
	  	 Changes in Corporate Structure
	  	3
	 Section 4.10.
	  	 Proceedings and Documents
	  	3
		
	 SECTION 5 REPRESENTATIONS AND WARRANTIES OF
THE COMPANY
	  	4
			
	 Section 5.1.
	  	 Organization; Power and Authority
	  	4
	 Section 5.2.
	  	 Authorization, etc
	  	4
	 Section 5.3.
	  	 Disclosure
	  	4
	 Section 5.4.
	  	 Organization and Ownership of Shares of Subsidiaries
	  	4
	 Section 5.5.
	  	 Financial Statements
	  	5
	 Section 5.6.
	  	 Compliance with Laws, Other Instruments, etc.
	  	5
	 Section 5.7.
	  	 Governmental Authorizations, etc.
	  	5
	 Section 5.8.
	  	 Litigation; Observance of Statutes and Orders
	  	6
	 Section 5.9.
	  	 Taxes
	  	6
	 Section 5.10.
	  	 Title to Property; Leases
	  	6
	 Section 5.11.
	  	 Licenses, Permits, etc.
	  	6
	 Section 5.12.
	  	 Compliance with ERISA
	  	7
	 Section 5.13.
	  	 Private Offering by the Company
	  	8
	 Section 5.14.
	  	 Use of Proceeds; Margin Regulations
	  	8
	 Section 5.15.
	  	 Existing Indebtedness
	  	8
	 Section 5.16.
	  	 Foreign Assets Control Regulations, etc.
	  	8
	 Section 5.17.
	  	 Status under Certain Statutes
	  	8
	 Section 5.18.
	  	 Environmental Matters
	  	9
			
	 SECTION 6.
	  	 REPRESENTATIONS OF THE PURCHASER
	  	9
			
	 Section 6.1.
	  	 Purchase for Investment
	  	9

  

 i 

 Exhibit 10(x) (continued) 
  

					
	 Section 6.2.
	  	 Source of Funds
	  	9
		
	 SECTION 7. INFORMATION AS TO
COMPANY
	  	11
			
	 Section 7.1.
	  	 Financial and Business Information
	  	11
	 Section 7.2.
	  	 Officer’s Certificate
	  	13
	 Section 7.3.
	  	 Inspection
	  	14
			
	 SECTION 8.
	  	 PREPAYMENT OF THE NOTES
	  	14
			
	 Section 8.1.
	  	 Intentionally Deleted
	  	14
	 Section 8.2.
	  	 Optional Prepayments with Make-Whole Amount
	  	14
	 Section 8.3.
	  	 Allocation of Partial Prepayments
	  	14
	 Section 8.4.
	  	 Maturity; Surrender, etc.
	  	15
	 Section 8.5.
	  	 Purchase of Notes
	  	15
	 Section 8.6.
	  	 Make-Whole Amount
	  	15
	 Section 8.7.
	  	 Change in Control
	  	17
			
	 SECTION 9.
	  	 AFFIRMATIVE COVENANTS
	  	18
			
	 Section 9.1.
	  	 Compliance with Law
	  	18
	 Section 9.2.
	  	 Insurance
	  	18
	 Section 9.3.
	  	 Maintenance of Properties
	  	19
	 Section 9.4.
	  	 Payment of Taxes
	  	19
	 Section 9.5.
	  	 Corporate Existence, etc.
	  	19
	 Section 9.6.
	  	 Pari Passu Ranking
	  	19
	 Section 9.7.
	  	 Line of Business
	  	20
			
	 SECTION 10.
	  	 NEGATIVE COVENANTS
	  	20
			
	 Section 10.1.
	  	 Transactions with Affiliates
	  	20
	 Section 10.2.
	  	 Merger, Consolidation, etc.
	  	20
	 Section 10.3.
	  	 Maintenance of Consolidated Net Worth
	  	21
	 Section 10.4.
	  	 Limitation on Consolidated Indebtedness
	  	21
	 Section 10.5.
	  	 Limitation on Priority Debt
	  	21
	 Section 10.6.
	  	 Sale of Assets
	  	21
	 Section 10.7.
	  	 Limitations on Liens
	  	21
			
	 SECTION 11.
	  	 EVENTS OF DEFAULT
	  	23
			
	 SECTION 12.
	  	 REMEDIES ON DEFAULT, ETC.
	  	25
			
	 Section 12.1.
	  	 Acceleration
	  	25
	 Section 12.2.
	  	 Other Remedies
	  	26
	 Section 12.3.
	  	 Rescission
	  	26
	 Section 12.4.
	  	 No Waivers or Election of Remedies, Expenses, etc.
	  	26
			
	 SECTION 13.
	  	 REGISTRATION; EXCHANGE; SUBSTITUTION OF
NOTES
	  	27
			
	 Section 13.1.
	  	 Registration of Notes
	  	27
	 Section 13.2.
	  	 Transfer and Exchange of Notes
	  	27
	 Section 13.3.
	  	 Replacement of Notes
	  	27
			
	 SECTION 14.
	  	 PAYMENTS ON NOTES
	  	28

  

 ii 

 Exhibit 10(x) (continued) 
  

					
	 Section 14.1.
	  	 Place of Payment
	  	28
	 Section 14.2.
	  	 Home Office Payment
	  	28
			
	 SECTION 15.
	  	 EXPENSES, ETC.
	  	29
			
	 Section 15.1.
	  	 Transaction Expenses
	  	29
	 Section 15.2.
	  	 Survival
	  	29
			
	 SECTION 16.
	  	 SURVIVAL OF REPRESENTATIONS AND WARRANTIES;
ENTIRE AGREEMENT
	  	29
			
	 SECTION 17.
	  	 AMENDMENT AND WAIVER
	  	29
			
	 Section 17.1.
	  	 Requirements
	  	29
	 Section 17.2.
	  	 Solicitation of Holders of Notes
	  	30
	 Section 17.3.
	  	 Binding Effect, etc.
	  	30
	 Section 17.4.
	  	 Notes Held by Company, etc.
	  	31
			
	 SECTION 18.
	  	 NOTICES
	  	31
			
	 SECTION 19.
	  	 REPRODUCTION OF DOCUMENTS
	  	31
			
	 SECTION 20.
	  	 CONFIDENTIAL INFORMATION
	  	32
			
	 SECTION 21.
	  	 SUBSTITUTION OF PURCHASER
	  	33
			
	 SECTION 22.
	  	 MISCELLANEOUS
	  	33
			
	 Section 22.1.
	  	 Successors and Assigns
	  	33
	 Section 22.2.
	  	 Payments Due on Non-Business Days
	  	33
	 Section 22.3.
	  	 Severability
	  	34
	 Section 22.4.
	  	 Construction
	  	34
	 Section 22.5.
	  	 Counterparts
	  	34
	 Section 22.6.
	  	 Governing Law
	  	34

  

					
			
	 SCHEDULE A
	  	—	  	Information Relating to Purchasers
			
	 SCHEDULE B
	  	—	  	Defined Terms
			
	 SCHEDULE 4.9
	  	—	  	Changes in Corporate Structure
			
	 SCHEDULE 5.3
	  	—	  	Disclosure Materials
			
	 SCHEDULE 5.4
	  	—	  	Subsidiaries of the Company and Ownership of Subsidiary Stock
			
	 SCHEDULE 5.5
	  	—	  	Financial Statements
			
	 SCHEDULE 5.8
	  	—	  	Certain Litigation
			
	 SCHEDULE 5.11
	  	—	  	Patents, etc.
			
	 SCHEDULE 5.14
	  	—	  	Use of Proceeds
			
	 SCHEDULE 5.15
	  	—	  	Existing Indebtedness
			
	 SCHEDULE 10.7(f)
	  	—	  	Existing Liens
			
	 EXHIBIT 1
	  	—	  	Form of 7.687% Senior Note due September 12, 2010
			
	 EXHIBIT 4.4
	  	—	  	Form of Opinion of Special Counsel for the Company

  

 iii 

 Exhibit 10(x) (continued) 
  

 SIGMA–ALDRICH CORPORATION 
 3050 SPRUCE STREET 
 ST. LOUIS, MISSOURI 63103 
 7.687% SENIOR NOTES due September 12, 2010 
 September 12, 2000 
 TO EACH OF THE PURCHASERS
LISTED IN 
     THE ATTACHED SCHEDULE A:

 Ladies and Gentlemen: 
 Sigma–Aldrich Corporation, a
Delaware corporation, together with its successors and assigns (the “Company”), agrees with you as follows: 
 SECTION 1. AUTHORIZATION OF NOTES. 
 The Company has authorized the
issue and sale of $100,000,000 aggregate principal amount of its 7.687% Senior Notes due September 12, 2010 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13 of this
Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized terms used in
this Agreement are defined in Schedule B; references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. 
 SECTION 2. SALE AND PURCHASE OF NOTES. 
 Subject to the terms and conditions of this Agreement, the Company will issue and sell to you and you will purchase from the Company, at the Closing provided for in
Section 3, Notes in the principal amount specified opposite your name in Schedule A at the purchase price of 100% of the principal amount thereof. 
 Contemporaneously with entering into this Agreement, the Company is entering into separate Note Purchase Agreements (the “Other Agreements”) identical with this Agreement with each of the other purchasers named in
Schedule A (the “Other Purchasers”), providing for the sale at such Closing to each of the Other Purchasers of Notes in the principal amount specified opposite its name in Schedule A. Your obligation hereunder and the
obligations of the Other Purchasers under the Other Agreements are several and not joint obligations and you shall have no obligation under any Other Agreement and no liability to any Person for the performance or nonperformance by any Other
Purchaser thereunder. 

 Exhibit 10(x) (continued) 
  

 SECTION 3. CLOSING. 
 The sale and purchase of the Notes to be purchased by you shall occur at the offices of Bryan Cave, LLP, 211 North Broadway, One Metropolitan Square, Suite 3600, St. Louis, Missouri 63102 at 10:00 a.m. CDT, at a closing (the
“Closing”) on September 12, 2000 or on such other Business Day thereafter on or prior to October 1, 2000 as may be agreed upon by the Company and you. At the Closing the Company will deliver to you the Notes to be purchased by
you in the form of a single Note dated the date of the Closing and registered in your name (or in the name of your nominee), against delivery by you to the Company or its order of immediately available funds in the amount of the purchase price
therefor by wire transfer of immediately available funds for the account of the Company to: Firstar Bank, N.A., ABA# 081-000-210, Account #1005017999, Account Name: Sigma-Aldrich Corporation. If at the Closing the Company shall fail to tender such
Notes to you as provided above in this Section 3, or any of the conditions specified in Section 4 shall not have been fulfilled to your satisfaction, you shall, at your election, be relieved of all further obligations under this Agreement,
without thereby waiving any rights you may have by reason of such failure or such nonfulfillment. 
 SECTION 4.
CONDITIONS TO CLOSING. 
 Your obligation to purchase and pay for the Notes to be sold to you at the Closing
is subject to the fulfillment to your satisfaction, prior to or at the Closing, of the following conditions: 
 Section 4.1.
Representations and Warranties. The representations and warranties of the Company in this Agreement shall be correct when made and at the time of the Closing. 
 Section 4.2. Performance; No Default. The Company shall have performed and complied with all agreements and conditions
contained in this Agreement required to be performed or complied with by it prior to or at the Closing and after giving effect to the issue and sale of the Notes (and the application of the proceeds thereof as contemplated by Schedule 5.14) no
Default or Event of Default shall have occurred and be continuing. 
 Section 4.3. Compliance
Certificates. 
 (a) Officer’s Certificate. The Company shall have delivered
to you an Officer’s Certificate, dated the date of the Closing, certifying that the conditions specified in Sections 4.1, 4.2 and 4.9 have been fulfilled. 
 (b) Secretary’s Certificate. The Company shall have delivered to you a certificate certifying as to the
resolutions attached thereto and other corporate proceedings relating to the authorization, execution and delivery of the Notes and the Agreements. 
  

 2 

 Exhibit 10(x) (continued) 
  

 Section 4.4. Opinions of Counsel. You shall have received an opinion in form and substance satisfactory to you,
dated the date of the Closing from Bryan Cave, counsel for the Company, covering the matters set forth in Exhibit 4.4 and covering such other matters incident to the transactions contemplated hereby as you or your counsel may reasonably request
(and the Company hereby instructs its counsel to deliver such opinion to you). 
 Section 4.5. Purchase Permitted by Applicable
Law, etc. On the date of the Closing your purchase of Notes shall (i) be permitted by the laws and regulations of each jurisdiction to which you are subject, without recourse to provisions (such as Section 1405(a)(8) of the
New York Insurance Law) permitting limited investments by insurance companies without restriction as to the character of the particular investment, (ii) not violate any applicable law or regulation (including, without limitation, Regulation G,
T or X of the Board of Governors of the Federal Reserve System) and (iii) not subject you to any tax, penalty or liability under or pursuant to any applicable law or regulation, which law or regulation was not in effect on the date hereof. If
requested by you, you shall have received an Officer’s Certificate certifying as to such matters of fact as you may reasonably specify to enable you to determine whether such purchase is so permitted. 
 Section 4.6. Sale of Other Notes. Contemporaneously with the Closing the Company shall sell to the Other Purchasers and the Other
Purchasers shall purchase the Notes to be purchased by them at the Closing as specified in Schedule A. 
 Section 4.7. Intentionally deleted. 
 Section 4.8. Private Placement Number.
A Private Placement Number issued by Standard & Poor’s CUSIP Service Bureau (in cooperation with the Securities Valuation Office of the National Association of Insurance Commissioners) shall have been requested by and obtained for
the Notes by the Purchaser. 
 Section 4.9. Changes in Corporate Structure. Except as specified in
Schedule 4.9, the Company shall not have changed its jurisdiction of incorporation or been a party to any merger or consolidation and shall not have succeeded to all or any substantial part of the liabilities of any other entity, at any time
following the date of the most recent financial statements referred to in Schedule 5.5. 
 Section 4.10. Proceedings and
Documents. All corporate and other proceedings in connection with the transactions contemplated by this Agreement and all documents and instruments incident to such transactions shall be satisfactory to you and your counsel, and you
and your counsel shall have received all such counterpart originals or certified or other copies of such documents as you or they may reasonably request. 
  

 3 

 Exhibit 10(x) (continued) 
  

 SECTION 5. REPRESENTATIONS AND WARRANTIES OF THE
COMPANY. 
 The Company represents and warrants to you as of the Date of the Closing that: 
 Section 5.1. Organization; Power and Authority. The Company is a corporation duly organized, validly existing and in good standing
under the laws of its jurisdiction of incorporation, and is duly qualified as a foreign corporation and is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which the failure
to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has the corporate power and authority to own or hold under lease the properties it purports to
own or hold under lease, to transact the business it transacts and proposes to transact, to execute and deliver this Agreement and the Other Agreements and the Notes and to perform the provisions hereof and thereof. 
 Section 5.2. Authorization, etc. This Agreement and the Other Agreements and the Notes have been duly authorized by all
necessary corporate action on the part of the Company, and this Agreement constitutes, and upon execution and delivery thereof each Note will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and
(ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 Section 5.3. Disclosure. The Company has executed and delivered to you that certain Commitment dated August 9, 2000 which contained a Term Sheet (the “Term Sheet”) summarizing the main
terms relating to the transactions completed herein. Except as disclosed in Schedule 5.3, this Agreement, the Term Sheet, the documents, certificates or other writings identified in Schedule 5.3 and the financial statements listed in
Schedule 5.5, taken as a whole, do not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made. Except
as disclosed in the Term Sheet or as expressly described in Schedule 5.3, or in one of the documents, certificates or other writings identified therein, or in the financial statements listed in Schedule 5.5, since December 31, 1999
there has been no change in the financial condition, operations, business or properties of the Company or any of its Subsidiaries except changes that individually or in the aggregate would not reasonably be expected to have a Material Adverse
Effect. 
 Section 5.4. Organization and Ownership of Shares of Subsidiaries. 
 (a) Schedule 5.4 is (except as noted therein) a complete and correct list of the Company’s Subsidiaries, showing, as to
each Subsidiary, the correct name thereof, the jurisdiction of its organization, and the percentage of shares of each class of its capital stock or similar equity interests outstanding owned by the Company and each other Subsidiary. 
  

 4 

 Exhibit 10(x) (continued) 
  

 (b) All of the outstanding shares of capital stock or similar equity interests of each Subsidiary shown in
Schedule 5.4 as being owned by the Company and its Subsidiaries have been validly issued, are fully paid and nonassessable and are owned by the Company or another Subsidiary free and clear of any Lien (except as otherwise disclosed in
Schedule 5.4). 
 (c) Each Subsidiary identified in Schedule 5.4 is a corporation or other legal entity duly
organized, validly existing and in good standing under the laws of its jurisdiction of organization, and is duly qualified as a foreign corporation or other legal entity and is in good standing in each jurisdiction in which such qualification is
required by law, other than those jurisdictions as to which the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each such Subsidiary has the
corporate or other power and authority to own or hold under lease the properties it purports to own or hold under lease and to transact the business it transacts and proposes to transact. 
 Section 5.5. Financial Statements. The Company has delivered to each Purchaser copies of the
financial statements of the Company and its Subsidiaries listed on Schedule 5.5. All of said financial statements (including in each case the related schedules and notes) fairly present in all material respects the consolidated financial
position of the Company and its Subsidiaries as of the respective dates specified in such Schedule and the consolidated results of their operations and cash flows for the respective periods so specified and have been prepared in accordance with GAAP
consistently applied throughout the periods involved except as set forth in the notes. 
 Section 5.6. Compliance with Laws, Other
Instruments, etc. The execution, delivery and performance by the Company of this Agreement and the Notes will not (x) contravene, result in any breach of, or constitute a default under, or result in the creation of any Lien in
respect of any property of the Company or any Subsidiary under any Material: (i) indenture; (ii) mortgage; (iii) deed of trust; (iv) loan; (v) purchase or credit agreement; (vi) lease; (vii) corporate charter or
by-laws; or (viii) any other agreement or instrument to which the Company or any Subsidiary is bound or by which the Company or any Subsidiary or any of their respective properties may be bound or affected, (y) conflict with or result in a
breach of any of the terms, conditions or provisions of any order, judgment, decree, or ruling of any court, arbitrator or Governmental Authority applicable to the Company or any Subsidiary or (z) violate any provision of any statute or other
rule or regulation of any Governmental Authority applicable to the Company or any Subsidiary. 
 Section 5.7. Governmental
Authorizations, etc. No consent, approval or authorization of, or registration, filing or declaration with, any Governmental Authority is required in connection with the execution, delivery or performance by the
Company of this Agreement or the Notes. 
  

 5 

 Exhibit 10(x) (continued) 
  

 Section 5.8. Litigation; Observance of Statutes and Orders. (a) Except as disclosed in
Schedule 5.8, there are no actions, suits or proceedings pending or, to the knowledge of the Company, threatened against or affecting the Company or any Subsidiary or any property of the Company or any Subsidiary in any court or before any
arbitrator of any kind or before or by any Governmental Authority that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. 
 (b) Neither the Company nor any Subsidiary is in default under any order, judgment, decree or ruling of any court, arbitrator or
Governmental Authority or is in violation of any applicable law, ordinance, rule or regulation (including without limitation Environmental Laws) of any Governmental Authority, which default or violation, individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect. 
 Section 5.9. Taxes. As of September 15,
1999, the Company and its Subsidiaries have filed all income tax returns that are required to have been filed in any jurisdiction, and have paid all taxes shown to be due and payable on such returns and all other taxes and assessments payable by
them, to the extent such taxes and assessments have become due and payable and before they have become delinquent, except for any taxes and assessments (i) the amount of which is not individually or in the aggregate Material or (ii) the
amount, applicability or validity of which is currently being contested in good faith by appropriate proceedings and with respect to which the Company or a Subsidiary, as the case may be, has established adequate reserves in accordance with GAAP.
The United States Federal income tax liabilities of the Company and its Subsidiaries have been determined, examined and accepted by the Internal Revenue Service and paid for all fiscal years up to and including the fiscal year ended
December 31, 1996. 
 Section 5.10. Title to Property; Leases. The Company and its Subsidiaries have
good and sufficient title to their respective Material properties, including all such properties reflected in the most recent audited balance sheet referred to in Section 5.5 or purported to have been acquired by the Company or any Subsidiary
after said date (except as sold or otherwise disposed of in the ordinary course of business), in each case free and clear of Liens prohibited by this Agreement, except for those defects in title and Liens that, individually or in the aggregate,
would not have a Material Adverse Effect. All Material leases are valid and subsisting and are in full force and effect in all material respects. 
 Section 5.11. Licenses, Permits, etc. Except as disclosed in Schedule 5.11, the Company and its Subsidiaries own or possess all licenses, permits, franchises, authorizations, patents,
copyrights, service marks, trademarks and trade names, or rights thereto, that are Material, without known conflict with the rights of others, except for those conflicts that, individually or in the aggregate, would not have a Material Adverse
Effect. 
  

 6 

 Exhibit 10(x) (continued) 
  

 Section 5.12. Compliance with ERISA. To the best of the Company’s knowledge: 
 (a) the Company and each ERISA Affiliate have operated and administered each Plan in compliance with all applicable laws except for
such instances of noncompliance as have not resulted in and could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any ERISA Affiliate has incurred any liability pursuant to Title I or IV of ERISA or
the penalty or excise tax provisions of the Code relating to employee benefit plans (as defined in Section 3 of ERISA), and no event, transaction or condition has occurred or exists that would reasonably be expected to result in the incurrence
of any such liability by the Company or any ERISA Affiliate, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate, in either case pursuant to Title I or IV of ERISA or to such penalty
or excise tax provisions or to Section 401(a)(29) or 412 of the Code, other than such liabilities or Liens as would not be individually or in the aggregate Material. 
 (b) The present value of the aggregate benefit liabilities under each of the Plans (other than Multi-employer Plans), determined as
of the end of such Plan’s most recently ended plan year on the basis of the actuarial assumptions specified for funding purposes in such Plan’s most recent actuarial valuation report, did not exceed the aggregate current value of the
assets of such Plan allocable to such benefit liabilities. The term “benefit liabilities” has the meaning specified in Section 4001 of ERISA and the terms “current value” and “present value” have the meaning
specified in Section 3 of ERISA. 
 (c) The Company and its ERISA Affiliates have not incurred withdrawal
liabilities (and are not subject to contingent withdrawal liabilities) under section 4201 or 4204 of ERISA in respect of Multi-employer Plans that individually or in the aggregate are Material. 
 (d) The expected post-retirement benefit obligation (determined as of the last day of the Company’s most recently ended fiscal
year in accordance with Financial Accounting Standards Board Statement No. 106, without regard to liabilities attributable to continuation coverage mandated by section 4980B of the Code) of the Company and its Subsidiaries is approximately
$42,600,000 as of December 31, 1999. 
 (e) The execution and delivery of this Agreement and the issuance and sale
of the Notes hereunder will not involve any transaction that is subject to the prohibitions of section 406 of ERISA or in connection with which a tax could be imposed pursuant to section 4975(c)(1)(A)-(D) of the Code. The representation by
the Company in the first sentence of this Section 5.12(e) is made in reliance upon and subject to (i) the accuracy of your representation in Section 6.2 as to the sources of the funds to be used to pay the purchase price of the Notes
to be purchased by you and (ii) the assumption, made solely for the purpose of making such representation, that Department of Labor Interpretive Bulletin 75-2 with respect to prohibited transactions remains valid in the circumstances of the
transactions contemplated herein. 
  

 7 

 Exhibit 10(x) (continued) 
  

 Section 5.13. Private Offering by the Company. Neither the Company nor anyone acting on its behalf has
offered the Notes or any similar securities for sale to, or solicited any offer to buy any of the same from, or otherwise approached or negotiated in respect thereof with, any person other than you, who has been offered the Notes at a private sale
for investment. Neither the Company nor anyone acting on its behalf has taken, or will take, any action that would subject the issuance or sale of the Notes to the registration requirements of Section 5 of the Securities Act. 
 Section 5.14. Use of Proceeds; Margin Regulations. The Company will apply the proceeds of the sale of the
Notes as set forth in Schedule 5.14. No part of the proceeds from the sale of the Notes hereunder will be used, directly or indirectly, for the purpose of buying or carrying any margin stock within the meaning of Regulation U of the Board
of Governors of the Federal Reserve System (12 CFR 221) other than the capital stock of the Company which will be immediately retired or held by the Company as treasury stock, or for the purpose of buying or carrying or trading in any
securities under such circumstances as to involve the Company in a violation of Regulation U of said Board (12 CFR 224) or to involve any broker or dealer in a violation of Regulation T of said Board (12 CFR 220). Margin stock
does not constitute more than 0% of the value of the consolidated assets of the Company and its Subsidiaries and the Company does not have any present intention that margin stock will constitute more than 0% of the value of such assets. As used in
this Section, the terms “margin stock” and “purpose of buying or carrying” shall have the meanings assigned to them in said Regulation U. 
 Section 5.15. Existing Indebtedness. Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Indebtedness of the Company
and its Subsidiaries as of July 31, 2000, since which date there has been no Material change in the amounts, interest rates, sinking funds, installment payments or maturities of the Indebtedness of the Company or its Subsidiaries. Neither the
Company nor any Subsidiary is in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of the Company or such Subsidiary and no event or condition exists with respect to any
Indebtedness of the Company or any Subsidiary the outstanding principal amount of which exceeds $10,000,000 that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Indebtedness to become
due and payable before its stated maturity or before its regularly scheduled dates of payment. 
 Section 5.16. Foreign Assets
Control Regulations, etc. Neither the sale of the Notes by the Company hereunder nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended, or any of the foreign
assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto. 
 Section 5.17. Status under Certain Statutes. Neither the Company nor any Subsidiary is
subject to regulation under the Investment Company Act of 1940, as amended, the Public Utility Holding Company Act of 1935, as amended, the Interstate Commerce Act, as amended, or the Federal Power Act, as amended. 
  

 8 

 Exhibit 10(x) (continued) 
  

 Section 5.18. Environmental Matters. Neither the Company nor any Subsidiary has knowledge of any claim or has received
any notice of any claim, and no proceeding has been instituted raising any claim against the Company or any of its Subsidiaries or any of their respective real properties now or formerly owned, leased or operated by any of them or other assets,
alleging any damage to the environment or violation of any Environmental Laws, except, in each case, such as could not reasonably be expected to result in a Material Adverse Effect. Except as otherwise disclosed to you in writing: 
 (a) neither the Company nor any Subsidiary has knowledge of any facts which would give rise to any claim, public or private, of
violation of Environmental Laws or damage to the environment emanating from, occurring on or in any way related to real properties now or formerly owned, leased or operated by any of them or to other assets or their use, except, in each case, such
as could not reasonably be expected to result in a Material Adverse Effect; 
 (b) neither the Company nor any of its
Subsidiaries has stored any Hazardous Materials on real properties now or formerly owned, leased or operated by any of them or disposed of any Hazardous Materials in a manner contrary to any Environmental Laws in each case in any manner that could
reasonably be expected to result in a Material Adverse Effect; and 
 (c) all buildings on all real properties now
owned, leased or operated by the Company or any of its Subsidiaries are in compliance with applicable Environmental Laws, except where failure to comply could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 6. REPRESENTATIONS OF THE PURCHASER. 
 Section 6.1. Purchase for Investment. You represent that you are purchasing the Notes for your own account or for one or more
separate accounts maintained by you or for the account of one or more pension or trust funds and not with a view to the distribution thereof, provided that the disposition of your or their property shall at all times be within your or their
control. You understand that the Notes have not been registered under the Securities Act and may be resold only if registered pursuant to the provisions of the Securities Act or if an exemption from registration is available, except under
circumstances where neither such registration nor such an exemption is required by law, and that the Company is not required to register the Notes. 
 Section 6.2. Source of Funds. You represent that at least one of the following statements is an accurate representation as to each source of funds (a “Source”) to be used by you to pay the purchase price
of the Notes to be purchased by you hereunder: 
 (a) if you are an insurance company, the Source does not include
assets allocated to any separate account maintained by you in which any employee benefit plan (or its related trust) has any interest, other than a separate account that is maintained 

  

 9 

 Exhibit 10(x) (continued) 
  

 
solely in connection with your fixed contractual obligations under which the amounts payable, or credited, to such plan and to any participant or beneficiary
of such plan (including any annuitant) are not affected in any manner by the investment performance of the separate account; or 
 (b) the Source is either (i) an insurance company pooled separate account, within the meaning of Prohibited Transaction Exemption (“PTE”) 90-1 (issued January 29, 1990), or (ii) a bank collective
investment fund, within the meaning of the PTE 91-38 (issued July 12, 1991) and, except as you have disclosed to the Company in writing pursuant to this paragraph (b), no employee benefit plan or group of plans maintained by the same employer
or employee organization beneficially owns more than 10% of all assets allocated to such pooled separate account or collective investment fund; or 
 (c) the Source constitutes assets of an “investment fund” (within the meaning of Part V of the QPAM Exemption) managed by a “qualified professional asset manager” or “QPAM” (within
the meaning of Part V of the QPAM Exemption), no employee benefit plan’s assets that are included in such investment fund, when combined with the assets of all other employee benefit plans established or maintained by the same employer or
by an affiliate (within the meaning of Section V(c)(1) of the QPAM Exemption) of such employer or by the same employee organization and managed by such QPAM, exceed 20% of the total client assets managed by such QPAM, the conditions of
Part I(c) and (g) of the QPAM Exemption are satisfied, neither the QPAM nor a person controlling or controlled by the QPAM (applying the definition of “control” in Section V(e) of the QPAM Exemption) owns a 5% or more interest in
the Company and (i) the identity of such QPAM and (ii) the names of all employee benefit plans whose assets are included in such investment fund have been disclosed to the Company in writing pursuant to this paragraph (c); or 

(d) the Source is a governmental plan; or 
 (e) the Source is one or more employee benefit plans, or a separate account or trust fund comprised of one or more employee benefit
plans, each of which has been identified to the Company in writing pursuant to this paragraph (e); or 
 (f) the Source
does not include assets of any employee benefit plan, other than a plan exempt from the coverage of ERISA; or 
 (g)
the Source is an “insurance company general account” within the meaning of PTE 95-60 (issued July 12, 1995) and there is no employee benefit plan, treating as a single plan, all plans maintained by the same employer or employee
organization, with respect to which the amount of the general account reserves and liabilities for all contracts held by or on behalf of such plan, exceed 10% of the total reserves and liabilities of such general account (exclusive of separate
account liabilities) plus surplus, as set forth in the NAIC Annual Statement filed with your state of domicile. 
  

 10 

 Exhibit 10(x) (continued) 
  

 
As used in this Section 6.2, the terms “employee benefit plan”, “governmental plan”, “party in interest” and
“separate account” shall have the respective meanings assigned to such terms in Section 3 of ERISA. 
 SECTION 7. INFORMATION AS TO COMPANY. 
 Section 7.1. Financial and Business Information. The Company shall deliver to each holder of Notes that is an Institutional Investor: 
 (a) Quarterly Statements. Within 60 days after the end of each quarterly fiscal period in each fiscal year of the
Company (other than the last quarterly fiscal period of each such fiscal year), duplicate copies of: 
 (i) a consolidated
balance sheet of the Company and its Subsidiaries as at the end of such quarter, and 
 (ii) consolidated statements of
income, changes in shareholders’ equity and cash flows of the Company and its Subsidiaries, for such quarter and (in the case of the second and third quarters) for the portion of the fiscal year ending with such quarter, 
 setting forth in each case in comparative form the figures for the corresponding periods in the previous fiscal year, all in reasonable detail, prepared in accordance
with GAAP applicable to quarterly financial statements generally, and certified by a Senior Financial Officer as fairly presenting, in all material respects, the financial position of the companies being reported on and their results of operations
and cash flows, subject to changes resulting from year-end adjustments, provided that delivery within the time period specified above of copies of the Company’s Quarterly Report on Form 10-Q prepared in compliance with the requirements
therefor and filed with the Securities and Exchange Commission shall be deemed to satisfy the requirements of this Section 7.1(a); 
 (b) Annual Statements. Within 105 days after the end of each fiscal year of the Company, duplicate copies of, 
 (i) a consolidated balance sheet of the Company and its Subsidiaries, as at the end of such year, and 
 (ii) consolidated statements of income, changes in shareholders’ equity and cash flows of the Company and its Subsidiaries, for such
year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail, prepared in accordance with GAAP, and accompanied by an opinion thereon of independent certified public accountants of
recognized national standing, which opinion shall state that such financial statements present fairly, in all material respects, the financial position of the companies being reported upon and their results of operations and cash flows and have been
prepared in conformity with GAAP, and that the examination of such accountants in connection with such financial statements has been 

  

 11 

 Exhibit 10(x) (continued) 
  

 
made in accordance with generally accepted auditing standards, and that such audit provides a reasonable basis for such opinion in the circumstances,
provided that the delivery within the time period specified above of the Company’s Annual Report on Form 10-K for such fiscal year (together with the Company’s annual report to shareholders, if any, prepared pursuant to
Rule 14a-3 under the Exchange Act) prepared in accordance with the requirements therefor and filed with the Securities and Exchange Commission shall be deemed to satisfy the requirements of this Section 7.1(b); 
 (c) SEC and Other Reports. Promptly upon their becoming available, one copy of (i) each financial statement,
report, notice or proxy statement sent by the Company or any Subsidiary to public securities holders generally, and (ii) each regular or periodic report, each registration statement that shall have become effective (without exhibits except as
expressly requested by such holder), and each final prospectus and all amendments thereto filed by the Company or any Subsidiary with the Securities and Exchange Commission; 
 (d) Notice of Default or Event of Default. Promptly, and in any event within five days after a Responsible Officer
becoming aware of the existence of any Default or Event of Default, a written notice specifying the nature and period of existence thereof and what action the Company is taking or proposes to take with respect thereto; 
 (e) ERISA Matters. Promptly, and in any event within five days after a Responsible Officer becoming aware of any of
the following, a written notice setting forth the nature thereof and the action, if any, that the Company or an ERISA Affiliate proposes to take with respect thereto: 
 (i) with respect to any Plan, any reportable event, as defined in section 4043(b) of ERISA and the regulations thereunder, for which
notice thereof has not been waived pursuant to such regulations as in effect on the date hereof; or 
 (ii) the taking by the
PBGC of steps to institute, or the threatening by the PBGC of the institution of, proceedings under section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Plan, or the receipt by the Company or any
ERISA Affiliate of a notice from a Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer Plan; or 
 (iii) any event, transaction or condition that could result in the incurrence of any liability by the Company or any ERISA Affiliate pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the
Code relating to employee benefit plans, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate pursuant to Title I or IV of ERISA or such penalty or excise tax provisions, if such liability
or Lien, taken together with any other such liabilities or Liens then existing, would reasonably be expected to have a Material Adverse Effect; 
  

 12 

 Exhibit 10(x) (continued) 
  

 (f) Requested Information. With reasonable promptness, such other data and information relating to the
business, operations, affairs, financial condition, assets or properties of the Company or any of its Subsidiaries or relating to the ability of the Company to perform its obligations hereunder and under the Notes as from time to time may be
reasonably requested by any such holder of Notes; 
 (g) Notices from Governmental Authority. Promptly,
and in any event within 30 days of receipt thereof, copies of any notice to the Company or any Subsidiary from any Federal or state Governmental Authority relating to any order, ruling, statute or other law or regulation that could reasonably be
expected to have a Material Adverse Effect; and 
 (h) Actions, Proceedings. Promptly after a Responsible
Officer becomes aware of the commencement thereof, notice of any action or proceeding relating to the Company or any Subsidiary in any court or before any Governmental Authority or arbitration board or tribunal as to which there is a reasonable
possibility of an adverse determination and that, if adversely determined, could reasonably be expected to have a Material Adverse Effect. 
 Section 7.2. Officer’s Certificate. Each set of financial statements delivered to a holder of Notes pursuant to Section 7.1(a) or Section 7.1(b) hereof shall be accompanied by a
certificate of a Senior Financial Officer setting forth: 
 (a) Covenant Compliance. The information
(including detailed calculations) required in order to establish whether the Company was in compliance with the requirements of Section 10 hereof, inclusive, during the quarterly or annual period covered by the statements then being furnished
(including with respect to each such Section, where applicable, the calculations of the maximum or minimum amount, ratio or percentage, as the case may be, permissible under the terms of such Sections, and the calculation of the amount, ratio or
percentage then in existence); and 
 (b) Event of Default. A statement that such officer has reviewed
the relevant terms hereof and has made, or caused to be made, under his or her supervision, a review of the transactions and conditions of the Company and its Subsidiaries from the beginning of the quarterly or annual period covered by the
statements then being furnished to the date of the certificate and that such review shall not have disclosed the existence during such period of any condition or event that constitutes a Default or an Event of Default or, if any such condition or
event existed or exists (including, without limitation, any such event or condition resulting from the failure of the Company or any Subsidiary to comply with any Environmental Law), specifying the nature and period of existence thereof and what
action the Company shall have taken or proposes to take with respect thereto. 
  

 13 

 Exhibit 10(x) (continued) 
  

 Section 7.3. Inspection. The Company shall permit the representatives of each holder of Notes that
is an Institutional Investor: 
 (a) No Default. If no Default or Event of Default then exists, at
the expense of such holder and upon reasonable prior notice to the Company, to visit the principal executive office of the Company, to discuss the affairs, finances and accounts of the Company and its Subsidiaries with the Company’s officers,
and, with the consent of the Company (which consent will not be unreasonably withheld) to visit the other offices and properties of the Company and each Subsidiary, all at such reasonable times and as often as may be reasonably requested in writing;
and 
 (b) Default. If a Default or Event of Default then exists, at the expense of the Company to visit
and inspect any of the offices or properties of the Company or any Subsidiary, to examine all their respective books of account, records, reports and other papers, to make copies and extracts therefrom, and to discuss their respective affairs,
finances and accounts with their respective officers and independent public accountants (and by this provision the Company authorizes said accountants to discuss the affairs, finances and accounts of the Company and its Subsidiaries), all at such
times and as often as may be requested. 
 SECTION 8. PREPAYMENT OF THE
NOTES. 
 Section 8.1. Intentionally deleted. 
 Section 8.2. Optional Prepayments with Make-Whole Amount. The Company may, at its option, upon notice as
provided below, prepay at any time all, or from time to time any part of, the Notes, in a principal amount of not less than $10,000,000 in the case of a partial prepayment, at 100% of the principal amount so prepaid, plus accrued interest plus the
Make-Whole Amount determined for the prepayment date with respect to such principal amount. The Company will give each holder of Notes written notice of each optional prepayment under this Section 8.2 not less than 30 days and not more than 60
days prior to the date fixed for such prepayment. Each such notice shall specify such date, the aggregate principal amount of the Notes to be prepaid on such date, the principal amount of each Note held by such holder to be prepaid (determined in
accordance with Section 8.3), and the interest to be paid on the prepayment date with respect to such principal amount being prepaid, and shall be accompanied by a certificate of a Senior Financial Officer as to the estimated Make-Whole Amount
due in connection with such prepayment (calculated as if the date of such notice were the date of the prepayment), setting forth the details of such computation. Two Business Days prior to such prepayment, the Company shall deliver to each holder of
Notes a certificate of a Senior Financial Officer specifying the calculation of such Make-Whole Amount as of the specified prepayment date. 
 Section 8.3. Allocation of Partial Prepayments. In the case of each partial prepayment of the Notes, the principal amount of the Notes to be prepaid shall be allocated among all of the Notes at the
time outstanding in proportion, as nearly as practicable, to the respective unpaid principal amounts thereof not theretofore called for prepayment. 
  

 14 

 Exhibit 10(x) (continued) 
  

 Section 8.4. Maturity; Surrender, etc. In the case of each prepayment
of Notes pursuant to this Section 8, the principal amount of each Note to be prepaid shall mature and become due and payable on the date fixed for such prepayment, together with interest on such principal amount accrued to such date and the
applicable Make-Whole Amount, if any. From and after such date, unless the Company shall fail to pay such principal amount when so due and payable, together with the interest and Make-Whole Amount, if any, as aforesaid, interest on such principal
amount shall cease to accrue. Any Note paid or prepaid in full shall be surrendered to the Company and cancelled and shall not be reissued, and no Note shall be issued in lieu of any prepaid principal amount of any Note. 
 Section 8.5. Purchase of Notes. The Company will not and will not permit any Affiliate to purchase, redeem, prepay or otherwise
acquire, directly or indirectly, any of the outstanding Notes except (a) upon the payment or prepayment of the Notes in accordance with the terms of this Agreement and the Notes or (b) pursuant to an offer to purchase made by the Company
or an Affiliate pro rata to the holders of all Notes at the time outstanding upon the same terms and conditions. Any such offer shall provide each holder with sufficient information to enable it to make an informed decision with respect to such
offer, and shall remain open for at least thirty (30) Business Days. If the holders of more than 50% of the principal amount of the Notes then outstanding accept such offer, the Company shall promptly notify the remaining holders of such fact
and the expiration date for the acceptance by holders of Notes of such offer shall be extended by the number of days necessary to give each such remaining holder at least fifteen (15) Business Days from its receipt of such notice to accept such
offer. The Company will promptly cancel all Notes acquired by it or any Affiliate pursuant to any payment, prepayment or purchase of Notes pursuant to any provision of this Agreement and no Notes may be issued in substitution or exchange for any
such Notes. 
 Section 8.6. Make-Whole Amount. The term “Make-Whole Amount” means, with respect to any
Note, an amount equal to the excess, if any, of the Discounted Value of the Remaining Scheduled Payments with respect to the Called Principal of such Note over the amount of such Called Principal, provided that the Make-Whole Amount may in no
event be less than zero. For the purposes of determining the Make-Whole Amount, the following terms have the following meanings: 
 “Called Principal” means, with respect to any Note, the principal of such Note that is to be prepaid pursuant to Section 8.2 or has become or is declared to be immediately due and payable pursuant to Section 12.1,
as the context requires. 
 “Discounted Value” means, with respect to the Called Principal of any Note, the
amount obtained by discounting all Remaining Scheduled Payments with respect to such Called Principal from their respective scheduled due dates to the Settlement Date with respect to such Called Principal, in accordance with accepted financial
practice and at a discount factor (applied on the same periodic basis as that on which interest on the Notes is payable) equal to the Reinvestment Yield with respect to such Called Principal. 
  

 15 

 Exhibit 10(x) (continued) 
  

 “Reinvestment Yield” means, with respect to the Called Principal of any Note, the sum of (a) .30%
plus (b) the yield to maturity implied by (i) the ask yields reported, as of the close of business on the second Business Day preceding the Settlement Date with respect to such Called Principal, on the “HP” (historical price)
pages for actively traded U.S. Treasury securities from the “PX1” page of the Bloomberg Financial Markets screens, having a maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date, or (ii) if
such yields are not reported as of such time or the yields reported as of such time are not ascertainable, the Treasury Constant Maturity Series Yields reported, for the latest day for which such yields have been so reported as of the second
Business Day preceding the Settlement Date with respect to such Called Principal, in U.S. Federal Reserve Statistical Release H.15 (519) (or any comparable successor publication) for actively traded U.S. Treasury securities having a constant
maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date. Such implied yield will be determined, if necessary, by (1) converting U.S. Treasury bill quotations to bond-equivalent yields in accordance with
accepted financial practice and (2) interpolating linearly between (A) the actively traded U.S. Treasury security with the maturity closest to and greater than the Remaining Average Life and (B) the actively traded U.S. Treasury
security with the maturity closest to and less than the Remaining Average Life. 
 “Remaining Average Life”
means, with respect to any Called Principal, the number of years (calculated to the nearest one-twelfth year) obtained by dividing 
 (i) such Called Principal into 
 (ii) the sum of the products obtained by multiplying 
 (A) the principal component of each Remaining Scheduled Payment with respect to such Called Principal by 
 (B) the number of years (calculated to the nearest one-twelfth year) that will elapse between the Settlement Date with respect to such
Called Principal and the scheduled due date of such Remaining Scheduled Payment. 
 “Remaining Scheduled
Payments” means, with respect to the Called Principal of any Note, all payments of such Called Principal and interest thereon that would be due after the Settlement Date with respect to such Called Principal if no payment of such Called
Principal were made prior to its scheduled due date, provided that if such Settlement Date is not a date on which interest payments are due to be made under the terms of the Notes, then the amount of the next succeeding scheduled interest payment
will be reduced by the amount of interest accrued to such Settlement Date and required to be paid on such Settlement Date pursuant to Section 8.2 or 12.1. 
  

 16 

 Exhibit 10(x) (continued) 
  

 “Settlement Date” means, with respect to the Called Principal of any Note, the date on which such Called
Principal is to be prepaid pursuant to Section 8.2 or has become or is declared to be immediately due and payable pursuant to Section 12.1, as the context requires. 
 Section 8.7. Change in Control. 
 (a) Notice of Change in Control or Control Event. The Company will, within fifteen (15) Business Days after any Responsible Officer has knowledge of the occurrence of any Change in Control or
Control Event, give written notice of such Change in Control or Control Event to each holder of Notes unless notice in respect of such Change in Control (or the Change in Control contemplated by such Control Event) shall have been given pursuant to
Section 8.7(b). If a Change in Control has occurred, such notice shall contain and constitute an offer to prepay Notes as described in Section 8.7(c) and shall be accompanied by the certificate described in Section 8.7(g). 

(b) Condition to Company Action. The Company will not take any action that consummates or finalizes a Change in Control
unless at least 30 days prior to such action it shall have given to each holder of Notes written notice containing and constituting an offer to prepay Notes as described in Section 8.7(c), accompanied by the certificate described in
Section 8.7(g), and contemporaneously with such action, it prepays all Notes required to be prepaid in accordance with this Section 8.7. 
 (c) Offer to Prepay Notes. The offer to prepay Notes contemplated by Section 8.7(a) and Section 8.7(b) shall be an offer to prepay, in accordance with and subject to this Section 8.7, all,
but not less than all, the Notes held by each holder (in this case only, “holder” in respect of any Note registered in the name of a nominee for a disclosed beneficial owner shall mean such beneficial owner) on a date specified in such
offer (the “Proposed Prepayment Date”). If such Proposed Prepayment Date is in connection with an offer contemplated by Section 8.7(a), such date shall be not less than 45 days and not more than 60 days after the date of such offer.
If the Proposed Prepayment Date shall not be specified in such offer, the Proposed Prepayment Date shall be the 60th day after the date of such offer. 
 (d) Acceptance and Rejection. A holder of Notes may accept the offer to prepay made pursuant to this Section 8.7 by causing a notice of such acceptance to be delivered to the Company at least
fifteen (15) days prior to the Proposed Prepayment Date. The failure by a holder of Notes to respond to an offer to prepay made pursuant to this Section 8.7 shall be deemed to constitute an acceptance of such offer by such holder.

 (e) Prepayment. Prepayment of the Notes to be prepaid pursuant to this Section 8.3 shall be at
100% of the principal amount of such Notes, together with interest on such Notes accrued to the date of prepayment. The prepayment shall be made on the Proposed Prepayment Date except as provided in Section 8.7(f). 
  

 17 

 Exhibit 10(x) (continued) 
  

 (f) Deferral of Obligation to Purchase. The obligation of the Company to prepay Notes pursuant to the offers
accepted in accordance with Section 8.7(d) is subject to the occurrence of the Change in Control in respect of which such offers and acceptances shall have been made. In the event that such Change in Control does not occur on the Proposed
Prepayment Date in respect thereof, the prepayment shall be deferred until and shall be made on the date on which such Change in Control occurs. The Company shall keep each holder of Notes reasonably and timely informed of: (i) any such
deferral of the date of prepayment; (ii) the date on which such Change in Control and the prepayment are expected to occur; and (iii) any determination by the Company that the efforts to effect such Change in Control have ceased or been
abandoned (in which case the offers and acceptances made pursuant to this Section 8.7 in respect of such Change in Control shall be deemed rescinded). 
 (g) Officer’s Certificate. Each offer to prepay the Notes pursuant to this Section 8.7 shall be accompanied by a certificate, executed by a Senior Financial Officer and dated the date of
such offer, specifying: (i) the Proposed Prepayment Date; (ii) that such offer is made pursuant to this Section 8.7; (iii) the principal amount of each Note offered to be prepaid; (iv) the interest that would be due on each
Note offered to be prepaid, accrued to the Proposed Prepayment Date; (v) the last date upon which the offer can be accepted or rejected, and setting forth the consequences of failing to provide an acceptance or rejection, as provided in
Section 8.7(d); (vi) that the conditions of this Section 8.7 have been fulfilled; and (vii) in reasonable detail, the nature and date or proposed date of the Change in Control. 
 SECTION 9. AFFIRMATIVE COVENANTS. 
 The Company covenants that so long as any of the Notes are outstanding: 
 Section 9.1. Compliance
with Law. The Company will and will cause each of its Subsidiaries to comply with all laws, ordinances or governmental rules or regulations to which each of them is subject, including, without limitation, Environmental Laws, and will obtain
and maintain in effect all licenses, certificates, permits, franchises and other governmental authorizations necessary to the ownership of their respective properties or to the conduct of their respective businesses, in each case to the extent
necessary to ensure that non-compliance with such laws, ordinances or governmental rules or regulations or failures to obtain or maintain in effect such licenses, certificates, permits, franchises and other governmental authorizations would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect on the business, operations, affairs, financial condition, properties or assets of the Company and its Subsidiaries taken as a whole. 
 Section 9.2. Insurance. The Company will and will cause each of its Subsidiaries to maintain, with financially sound and reputable
insurers, insurance with respect to their respective properties and businesses against such casualties and contingencies, of such types, on such terms and in such amounts (including deductibles, co-insurance and self-insurance, if adequate reserves
are maintained with respect thereto) as is customary in the case of entities of established reputations engaged in the same or a similar business and similarly situated. 
  

 18 

 Exhibit 10(x) (continued) 
  

 Section 9.3. Maintenance of Properties. The Company will and will cause each of its Subsidiaries to maintain and keep,
or cause to be maintained and kept, their respective properties in good repair, working order and condition (other than ordinary wear and tear), so that the business carried on in connection therewith may be properly conducted at all times,
provided that this Section shall not prevent the Company or any Subsidiary from discontinuing the operation and the maintenance of any of its properties if such discontinuance is desirable in the conduct of its business and the Company
has concluded that such discontinuance would not, individually or in the aggregate, have a Material Adverse Effect on the business, operations, affairs, financial condition, properties or assets of the Company and its Subsidiaries taken as a whole.

 Section 9.4. Payment of Taxes. The Company will and will cause each of its Subsidiaries to file all income tax or
similar tax returns required to be filed in any jurisdiction and to pay and discharge all taxes shown to be due and payable on such returns and all other taxes, assessments, governmental charges, or levies payable by any of them, to the extent such
taxes and assessments have become due and payable and before they have become delinquent, provided that neither the Company nor any Subsidiary need pay any such tax or assessment if (i) the amount, applicability or validity thereof is
contested by the Company or such Subsidiary on a timely basis in good faith and in appropriate proceedings, and the Company or a Subsidiary has established adequate reserves therefor in accordance with GAAP on the books of the Company or such
Subsidiary or (ii) the nonpayment of all such taxes and assessments in the aggregate would not reasonably be expected to have a Material Adverse Effect on the business, operations, affairs, financial condition, properties or assets of the
Company and its Subsidiaries taken as a whole. 
 Section 9.5. Corporate Existence, etc. The Company will at all times
preserve and keep in full force and effect its corporate existence. Subject to Sections 10.2 and 10.6, the Company will at all times preserve and keep in full force and effect the corporate existence of each of its Subsidiaries (unless merged
into the Company or a Subsidiary) and all rights and franchises of the Company and its Subsidiaries unless, in the good faith judgment of the Company, the termination of or failure to preserve and keep in full force and effect such corporate
existence, right or franchise would not, individually or in the aggregate, have a Material Adverse Effect on the business, operations, affairs, financial condition, properties or assets of the Company and its Subsidiaries taken as a whole.

 Section 9.6 Pari Passu Ranking. The Notes shall at all times rank pari passu, without preference or
priority, with all other outstanding, unsecured, unsubordinated obligations of the Company, present and future, that have not been accorded preferential rights. 
  

 19 

 Exhibit 10(x) (continued) 
  

 Section 9.7. Line of Business. The Company will, and will cause each of its Subsidiaries to carry on their
business in substantially the same manner and in substantially the same fields as such business is carried on and maintained as of the date of the Closing. 
 SECTION 10. NEGATIVE COVENANTS. 
 The Company covenants that so long as any of the Notes
are outstanding: 
 Section 10.1. Transactions with Affiliates. The Company will not and will not permit any Subsidiary to
enter into directly or indirectly any Material transaction or Material group of related transactions (including without limitation the purchase, lease, sale or exchange of properties of any kind or the rendering of any service) with any Affiliate
(other than the Company or another Subsidiary), except pursuant to the reasonable requirements of the Company’s or such Subsidiary’s business and upon fair and reasonable terms no less favorable to the Company or such Subsidiary than would
be obtainable in a comparable arm’s-length transaction with a Person not an Affiliate. 
 Section 10.2. Merger,
Consolidation, etc. The Company shall not consolidate with or merge with any other corporation or convey, transfer or lease substantially all of its assets in a single transaction or series of transactions to any Person (except that a
Subsidiary of the Company may: (x) consolidate with or merge with, or convey, transfer or lease substantially all of its assets in a single transaction or series of transactions to the Company or another Subsidiary of the Company; and
(y) convey, transfer or lease all of its assets in compliance with the provisions of Section 10.6) unless: 
 (a)
the successor formed by such consolidation or the survivor of such merger or the Person that acquires by conveyance, transfer or lease substantially all of the assets of the Company as an entirety, as the case may be (the “Successor
Corporation”), shall be a solvent corporation organized and existing under the laws of the United States or any State thereof (including the District of Columbia), and, if the Company is not such corporation, such corporation shall have
executed and delivered to each holder of any Notes its assumption of the due and punctual performance and observance of each covenant and condition of this Agreement, the Other Agreements and the Notes; and 
 (b) the Successor Corporation would he permitted to incur at least $1.00 of additional Indebtedness owing to a Person other than a
Subsidiary or Successor Corporation; and 
 (c) immediately after giving effect to such transaction, no Default or
Event of Default shall have occurred and be continuing. 
 No such conveyance, transfer or lease of substantially all of the assets of the Company shall have
the effect of releasing the Company or any successor corporation that shall theretofore have become such in the manner prescribed in this Section 10.2 from its liability under this Agreement or the Notes. 
  

 20 

 Exhibit 10(x) (continued) 
  

 Section 10.3. Maintenance of Consolidated Net Worth. The Company will not, at any time, permit Consolidated Net Worth to
be less than $750,000,000. 
 Section 10.4. Limitation on Consolidated Indebtedness. The Company will not, at any time
permit Consolidated Indebtedness to exceed 55% of the Consolidated Capitalization. 
 Section 10.5. Limitation on Priority Debt.
The Company will not, at any time, permit Priority Debt to exceed 30% of the Consolidated Net Worth as of the then most recently ended fiscal quarter of the Company. 
 Section 10.6. Sale of Assets. The Company will not, and will not permit any Subsidiary to, make any asset sale unless:

 (a) the Book Value of the property subject to such asset sale, together with the aggregate Book Value of all
property of the Company and its Subsidiaries that were the subject of an asset sale during the then current fiscal year of the Company, would not exceed 20% of Consolidated Total Assets determined as of the end of the then most recently ended fiscal
year of the Company; and, provided further that the cumulative Book Value of all property sold in accordance with this Section 10.6 will not exceed 30% of Consolidated Total Assets existing at the end of the most recent fiscal quarter; or

 (b) the sale proceeds equal or exceed the fair market value (as determined in the good faith opinion of the board of
directors of the Company) and where sale proceeds are used to acquire productive assets or to reduce Indebtedness not subordinate to these Notes within twelve (12) months of the asset sale; and 
 (c) in the event of any asset sale in accordance with Section 10.6 (a) or (b), immediately after giving effect to such
asset sale, no Default or Event of Default would exist. 
 Section 10.7. Limitations on Liens. The Company will
not, and will not permit any of its Subsidiaries to, directly or indirectly create, incur, assume or permit to exist (upon the happening of a contingency or otherwise) any Lien on or with respect to any property or asset (including, without
limitation, any document or instrument in respect of goods or accounts receivable) of the Company or any such Subsidiary, whether now owned or held or hereafter acquired, or any income or profits therefrom, or assign or otherwise convey any right to
receive income or profits, except: 
 (a) Liens for taxes, assessments or other governmental charges which are not yet
due and payable or the payment of which is not at the time required by Section 9.4; 
  

 21 

 Exhibit 10(x) (continued) 
  

 (b) Liens (other than any Lien imposed by ERISA) incurred or deposits made in the ordinary course of business
(i) in connection with workers’ compensation, unemployment insurance and other types of social security or retirement benefits, or (ii) to secure (or to obtain letters of credit that secure) the performance of tenders, statutory
obligations, surety bonds, appeal bonds, bids, leases (other than Capital Leases), performance bonds, purchase, construction or sales contracts and other similar obligations, in each case not incurred or made in connection with the borrowing of
money, the obtaining of advances or credit or the payment of the deferred purchase price of property; 
 (c) any
attachment or judgment Lien, unless the judgment it secures shall not, within sixty (60) days after the entry thereof, have been discharged or execution thereof stayed pending appeal; 
 (d) leases or subleases granted to others, easements, rights-of-way, restrictions and other similar charges or encumbrances, in
each case incidental to, and not interfering with, the ordinary conduct of the business of the Company or any of its Subsidiaries, provided that such Liens do not, in the aggregate, materially detract from the value of such property;

 (e) Liens on property or assets of any Subsidiary securing Indebtedness owing to the Company or to another
Subsidiary; 
 (f) Liens existing on the date of this Agreement and securing Indebtedness of the Company and its
Subsidiaries as listed on Schedule 10.7(f); 
 (g) any Lien created to secure all or any part of the purchase price, or
to secure Indebtedness incurred or assumed to pay all or any part of the purchase price or cost of construction, of property (or any improvement thereon) acquired or constructed by the Company or a Subsidiary after the date of the Closing,
provided that: 
 (i) any such Lien shall extend solely to the item or items of such property (or improvement thereon)
so acquired or constructed and, if required by the terms of the instrument originally creating such Lien, other property (or improvement thereon) which is an improvement to or is acquired for specific use in connection with such acquired or
constructed property (or improvement thereon) or which is real property being improved by such acquired or constructed property (or improvement thereon), 
 (ii) the principal amount of the Indebtedness secured by any such Lien shall at no time exceed an amount equal to 100% of the lesser of (A) the cost to the Company or such Subsidiary of the property (or
improvement thereon) so acquired or constructed and (B) the fair market value (as determined in good faith by the board of directors of the Company) of such property (or improvement thereon) at the time of such acquisition or construction, and

  

 22 

 Exhibit 10(x) (continued) 
  

 (iii) any such Lien shall be created contemporaneously with, or within180 days after, the acquisition or construction of
such property; 
 (h) any Lien existing on property of a Person immediately prior to its being consolidated with or
merged into the Company or a Subsidiary or its becoming a Subsidiary, or any Lien existing on any property acquired by the Company or any Subsidiary at the time such property is so acquired (whether or not the Indebtedness secured thereby shall have
been assumed), provided that (i) no such Lien shall have been created or assumed in contemplation of such consolidation or merger or such Person’s becoming a Subsidiary or such acquisition of property, and (ii) each such Lien
shall extend solely to the item or items of property so acquired and, if required by the terms of the instrument originally creating such Lien, other property which is an improvement to or is acquired for specific use in connection with such
acquired property; 
 (i) any Lien renewing, extending or refunding any Lien permitted by paragraphs (a) through
(h) of this Section 10.7, provided that: (i) the principal amount of Indebtedness secured by such Lien immediately prior to such extension, renewal or refunding is not increased or the maturity thereof reduced; (ii) such
Lien is not extended to any other property; (iii) immediately after such extension, renewal or refunding no Default or Event of Default would exist; and (iv) the weighted average life to maturity of the Indebtedness secured by such Lien(s)
is not reduced; 
 (j) other Liens not otherwise permitted by paragraphs (a) through (i) provided that such
Liens be considered Priority Debt. 
 SECTION 11. EVENTS OF DEFAULT. 
 An “Event of Default” shall exist if any of the following conditions or events shall occur and be continuing: 
 (a) the Company defaults in the payment of any principal or Make-Whole Amount, if any, on any Note when the same becomes due and
payable, whether at maturity or at a date fixed for prepayment or by declaration or otherwise; or 
 (b) the Company
defaults in the payment of any interest on any Note for more than five Business Days after the same becomes due and payable; or 
 (c) the Company defaults in the performance of or compliance with any term contained in Sections 10.3, 10.4, 10.5 or 10.6; 
 (d) the Company defaults in the performance of or compliance with any term contained in Sections 10.1, 10.2, 10.7, 10.8, 10.9, or 10.10 and such default is not remedied within fifteen (15) days after the
earlier of (i) a Responsible Officer obtaining actual knowledge of such default and (ii) the Company receiving written notice of such default from any holder of a Note (any such written notice to be identified as a “notice of
default” and to refer specifically to this paragraph (d) of Section 11); or 
  

 23 

 Exhibit 10(x) (continued) 
  

 (e) the Company defaults in the performance of or compliance with any term contained herein (other than those
referred to in paragraphs (a), (b), (c) and (d) of this Section 11) and such default is not remedied within 30 days after the earlier of (i) a Responsible Officer obtaining actual knowledge of such default and (ii) the
Company receiving written notice of such default from any holder of a Note (any such written notice to be identified as a “notice of default” and to refer specifically to this paragraph (e) of Section 11); or 
 (f) any representation or warranty made in writing by or on behalf of the Company or by any officer of the Company in this
Agreement or in any writing furnished in connection with the transactions contemplated hereby proves to have been false or incorrect in any material respect on the date as of which made; or 
 (g) the Company or any Subsidiary is in default (as principal or as guarantor or other surety): (i) in the payment of any
principal of or premium or make-whole amount or interest on any Indebtedness that is outstanding in an aggregate principal amount of at least $10,000,000 beyond any period of grace provided with respect thereto, or (ii) in the performance of or
compliance with any term of any evidence of any Indebtedness in an aggregate outstanding principal amount of at least $10,000,000 or of any mortgage, indenture or other agreement relating thereto or any other condition exists, and as a consequence
of such default or condition such Indebtedness has become, or has been declared due and payable before its stated maturity or before its regularly scheduled dates of payment; or 
 (h) the Company or any Subsidiary (i) is generally not paying, or admits in writing its inability to pay, its debts as they
become due, (ii) files, or consents by answer or otherwise to the filing against it of, a petition for relief or reorganization or arrangement or any other petition in bankruptcy, for liquidation or to take advantage of any bankruptcy,
insolvency, reorganization, moratorium or other similar law of any jurisdiction, (iii) makes an assignment for the benefit of its creditors, (iv) consents to the appointment of a custodian, receiver, trustee or other officer with similar
powers with respect to it or with respect to any substantial part of its property, (v) is adjudicated as insolvent or to be liquidated, or (vi) takes corporate action for the purpose of any of the foregoing; or 
 (i) a court or governmental authority of competent jurisdiction enters an order appointing, without consent by the Company or any
of its Subsidiaries, a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, or constituting an order for relief or approving a petition for relief or
reorganization or any other petition in bankruptcy or for liquidation or to take advantage of any bankruptcy or insolvency law of any jurisdiction, or ordering the dissolution, winding-up or liquidation of the Company or any of its Subsidiaries, or
any such petition shall be filed against the Company or any of its Subsidiaries and such petition shall not be dismissed within 60 days; or 
  

 24 

 Exhibit 10(x) (continued) 
  

 (j) an uninsured final judgment or judgments for the payment of money aggregating in excess of $10,000,000 are
rendered against one or more of the Company and its Subsidiaries and which judgments are not, within 60 days after entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within 60 days after the expiration of such stay; or

 (k) if (i) any Plan shall fail to satisfy the minimum funding standards of ERISA or the Code for any plan year
or part thereof or a waiver of such standards or extension of any amortization period is sought or granted under section 412 of the Code, (ii) a notice of intent to terminate any Plan shall have been or is reasonably expected to be filed
with the PBGC or the PBGC shall have instituted proceedings under ERISA section 4042 to terminate or appoint a trustee to administer any Plan or the PBGC shall have notified the Company or any ERISA Affiliate that a Plan may become a subject of
any such proceedings, (iii) the aggregate “amount of unfunded benefit liabilities” (within the meaning of section 4001(a)(18) of ERISA) under all Plans, determined in accordance with Title IV of ERISA, shall exceed 5% of
Consolidated Net Worth, (iv) the Company or any ERISA Affiliate shall have incurred or is reasonably expected to incur any liability pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee
benefit plans, (v) the Company or any ERISA Affiliate withdraws from any Multiemployer Plan, or (vi) the Company or any Subsidiary establishes or amends any employee welfare benefit plan that provides post-employment welfare benefits in a
manner that would increase the liability of the Company or any Subsidiary thereunder; and any such event or events described in clauses (i), (ii), (iv), (v) and (vi) above, either individually or together with any other such event or
events, would reasonably be expected to have a Material Adverse Effect. 
 As used in Section 11(j), the terms “employee benefit plan” and
“employee welfare benefit plan” shall have the respective meanings assigned to such terms in Section 3 of ERISA. 
 SECTION 12. REMEDIES ON DEFAULT, ETC. 
 Section 12.1. Acceleration. (a) If an Event of Default with respect to the Company described in paragraph (h) or (i) of Section 11 (other than an Event of Default described in clause (i) of
paragraph (h) or described in clause (vi) of paragraph (h) by virtue of the fact that such clause encompasses clause (i) of paragraph (h)) has occurred, all the Notes then outstanding shall automatically become immediately due
and payable. 
 (b) If any other Event of Default has occurred and is continuing, any holder or holders of more than
50% in principal amount of the Notes at the time outstanding may at any time at its or their option, by notice or notices to the Company, declare all the Notes then outstanding to be immediately due and payable. 
 (c) If any Event of Default described in paragraph (a) or (b) of Section 11 has occurred and is continuing, any
holder or holders of Notes at the time outstanding affected by such Event of Default may at any time, at its or their option, by notice or notices to the Company, declare all the Notes held by it or them to be immediately due and payable.

  

 25 

 Exhibit 10(x) (continued) 
  

 Upon any Notes becoming due and payable under this Section 12.1, whether automatically or by declaration, such Notes will forthwith mature and the
entire unpaid principal amount of such Notes, plus (x) all accrued and unpaid interest thereon and (y) the Make-Whole Amount determined in respect of such principal amount (to the full extent permitted by applicable law), shall all be
immediately due and payable, in each and every case without presentment, demand, protest or further notice, all of which are hereby waived. The Company acknowledges, and the parties hereto agree, that each holder of a Note has the right to maintain
its investment in the Notes free from repayment by the Company (except as herein specifically provided for) and that the provision for payment of a Make-Whole Amount by the Company in the event that the Notes are prepaid or are accelerated as a
result of an Event of Default, is intended to provide compensation for the deprivation of such right under such circumstances. 
 Section 12.2. Other Remedies. If any Default or Event of Default has occurred and is continuing, and irrespective of whether any Notes have become or have been declared immediately due and payable under Section 12.1,
the holder of any Note at the time outstanding may proceed to protect and enforce the rights of such holder by an action at law, suit in equity or other appropriate proceeding, whether for the specific performance of any agreement contained herein
or in any Note, or for an injunction against a violation of any of the terms hereof or thereof, or in aid of the exercise of any power granted hereby or thereby or by law or otherwise. 
 Section 12.3. Rescission. At any time after any Notes have been declared due and payable pursuant to clause (b) of
Section 12.1, the holders of not less than 50% in principal amount of the Notes then outstanding, by written notice to the Company, may rescind and annul any such declaration and its consequences if (a) the Company has paid all overdue
interest on the Notes, all principal of and Make-Whole Amount, if any, on any Notes that are due and payable and are unpaid other than by reason of such declaration, and all interest on such overdue principal and Make-Whole Amount, if any, and (to
the extent permitted by applicable law) any overdue interest in respect of the Notes, at the Default Rate, (b) all Events of Default and Defaults, other than non-payment of amounts that have become due solely by reason of such declaration, have
been cured or have been waived pursuant to Section 17, and (c) no judgment or decree has been entered for the payment of any monies due pursuant hereto or to the Notes. No rescission and annulment under this Section 12.3 will extend
to or affect any subsequent Event of Default or Default or impair any right consequent thereon. 
 Section 12.4. No Waivers or
Election of Remedies, Expenses, etc. No course of dealing and no delay on the part of any holder of any Note in exercising any right, power or remedy shall operate as a waiver thereof or otherwise prejudice such holder’s rights, powers
or remedies. No right, power or remedy conferred by this Agreement or by any Note upon any holder thereof shall be exclusive of any other right, power or remedy referred to herein or therein or now or hereafter available at law, in equity, by
statute or 

  

 26 

 Exhibit 10(x) (continued) 
  

 
otherwise. Without limiting the obligations of the Company under Section 15, the Company will pay to the holder of each Note on demand such further
amount as shall be sufficient to cover all costs and expenses of such holder incurred in any enforcement or collection under this Section 12, including, without limitation, reasonable attorneys’ fees, expenses and disbursements.

 SECTION 13. REGISTRATION; EXCHANGE; SUBSTITUTION OF
NOTES 
 Section 13.1. Registration of Notes. The Company shall keep
at its principal executive office a register for the registration and registration of transfers of Notes. The name and address of each holder of one or more Notes, each transfer thereof and the name and address of each transferee of one or more
Notes shall be registered in such register. Prior to due presentment for registration of transfer, the Person in whose name any Note shall be registered shall be deemed and treated as the owner and holder thereof for all purposes hereof, and the
Company shall not be affected by any notice or knowledge to the contrary. The Company shall give to any holder of a Note that is an Institutional Investor promptly upon request therefor, a complete and correct copy of the names and addresses of all
registered holders of Notes. 
 Section 13.2. Transfer and Exchange of Notes. Upon surrender of any Note at the
principal executive office of the Company for registration of transfer or exchange (and in the case of a surrender for registration of transfer, duly endorsed or accompanied by a written instrument of transfer duly executed by the registered holder
of such Note or his attorney duly authorized in writing and accompanied by the address for notices of each transferee of such Note or part thereof), the Company shall execute and deliver, at the Company’s expense (except as provided below), one
or more new Notes (as requested by the holder thereof) in exchange therefor, in an aggregate principal amount equal to the unpaid principal amount of the surrendered Note. Each such new Note shall be payable to such Person as such holder may request
and shall be substantially in the form of Exhibit 1. Each such new Note shall be dated and bear interest from the date to which interest shall have been paid on the surrendered Note or dated the date of the surrendered Note if no interest shall
have been paid thereon. The Company may require payment of a sum sufficient to cover any stamp tax or governmental charge imposed in respect of any such transfer of Notes. Notes shall not be transferred in denominations of less than $1,000,000,
provided that if necessary to enable the registration of transfer by a holder of its entire holding of Notes, one Note may be in a denomination of less than $1,000,000. Any transferee, by its acceptance of a Note registered in its name (or
the name of its nominee), shall be deemed to have made the representation set forth in Section 6.2. 
 Section 13.3.
Replacement of Notes. Upon receipt by the Company of evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note (which evidence shall be, in the case of an Institutional
Investor, notice from such Institutional Investor of such ownership and such loss, theft, destruction or mutilation), and 
  

 27 

 Exhibit 10(x) (continued) 
  

 (a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to it (provided that if
the holder of such Note is, or is a nominee for, an original Purchaser or another holder of a Note with a minimum net worth of at least $100,000,000, such Person’s own unsecured agreement of indemnity shall be deemed to be satisfactory), or

 (b) in the case of mutilation, upon surrender and cancellation thereof, the Company at its own expense shall execute
and deliver, in lieu thereof, a new Note, dated and bearing interest from the date to which interest shall have been paid on such lost, stolen, destroyed or mutilated Note or dated the date of such lost, stolen, destroyed or mutilated Note if no
interest shall have been paid thereon. 
 SECTION 14. PAYMENTS ON NOTES. 

Section 14.1. Place of Payment. Subject to Section 14.2, payments of principal, Make-Whole Amount, if any, and interest
becoming due and payable on the Notes shall be made in St. Louis, Missouri at the principal office of the Company in such jurisdiction. The Company may at any time, by notice to each holder of a Note, change the place of payment of the Notes so long
as such place of payment shall be either the principal office of the Company in such jurisdiction or the principal office of a bank or trust company in such jurisdiction. 
 Section 14.2. Home Office Payment. So long as you or your nominee shall be the holder of any Note, and notwithstanding anything contained in Section 14.1 or in such Note to the contrary, the
Company will pay all sums becoming due on such Note for principal, Make-Whole Amount, if any, and interest by the method and at the address specified for such purpose below your name in Schedule A, or by such other method or at such other
address as you shall have from time to time specified to the Company in writing for such purpose, without the presentation or surrender of such Note or the making of any notation thereon, except that upon written request of the Company made
concurrently with or reasonably promptly after payment or prepayment in full of any Note, you shall surrender such Note for cancellation, reasonably promptly after any such request, to the Company at its principal executive office or at the place of
payment most recently designated by the Company pursuant to Section 14.1. Prior to any sale or other disposition of any Note held by you or your nominee you will, at your election, either endorse thereon the amount of principal paid thereon and
the last date to which interest has been paid thereon or surrender such Note to the Company in exchange for a new Note or Notes pursuant to Section 13.2. The Company will afford the benefits of this Section 14.2 to any Institutional
Investor that is the direct or indirect transferee of any Note purchased by you under this Agreement and that has made the same agreement relating to such Note as you have made in this Section 14.2. 
  

 28 

 Exhibit 10(x) (continued) 
  

 SECTION 15. EXPENSES, ETC. 
 Section 15.1. Transaction Expenses. The Company will pay all costs and expenses (including reasonable attorneys’ fees of a special
counsel and, if reasonably required, local or other counsel) incurred by you and each Other Purchaser or holder of a Note in connection with any amendments, waivers or consents under or in respect of this Agreement or the Notes (whether or not such
amendment, waiver or consent becomes effective), including, without limitation: (a) the costs and expenses incurred in enforcing or defending (or determining whether or how to enforce or defend) any rights under this Agreement or the Notes or
in responding to any subpoena or other legal process or informal investigative demand issued in connection with this Agreement or the Notes, or by reason of being a holder of any Note, and (b) the costs and expenses, including financial
advisors’ fees, incurred in connection with the insolvency or bankruptcy of the Company or any Subsidiary or in connection with any work-out or restructuring of the transactions contemplated hereby and by the Notes. 
 Section 15.2. Survival. The obligations of the Company under this Section 15 will survive the payment or transfer of any Note,
the enforcement, amendment or waiver of any provision of this Agreement or the Notes, and the termination of this Agreement. 
 SECTION 16. SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE AGREEMENT. 
 All representations and warranties contained herein shall survive the execution and delivery of this Agreement and the Notes, the purchase or transfer by
you of any Note or portion thereof or interest therein and the payment of any Note, and may be relied upon by any subsequent holder of a Note, regardless of any investigation made at any time by or on behalf of you or any other holder of a Note. All
statements contained in any certificate or other instrument delivered by or on behalf of the Company pursuant to this Agreement shall be deemed representations and warranties of the Company under this Agreement. Subject to the preceding sentence,
this Agreement and the Notes embody the entire agreement and understanding between you and the Company and supersede all prior agreements and understandings relating to the subject matter hereof. 
 SECTION 17. AMENDMENT AND WAIVER. 
 Section 17.1. Requirements. This Agreement and the Notes may be amended, and the observance of any term hereof or of the Notes may be
waived (either retroactively or prospectively), with (and only with) the written consent of the Company and the Required Holders, except that (a) no amendment or waiver of any of the provisions of Section 1, 2, 3, 4, 5, 6 or 21 hereof, or
any defined term (as it is used therein), will be effective as to you unless consented to by you in writing, and (b) no such amendment or waiver may, without the written consent of the holder of each Note at the time outstanding affected
thereby, (i) subject to the provisions of Section 12 relating to acceleration or rescission, change the amount or time of any prepayment or payment of principal of, or reduce the 

  

 29 

 Exhibit 10(x) (continued) 
  

 
rate or change the time of payment or method of computation of interest or of the Make-Whole Amount on, the Notes, (ii) change the percentage of the
principal amount of the Notes the holders of which are required to consent to any such amendment or waiver, or (iii) amend any of Sections 8, 11(a), 11(b), 12, 17 or 20. 
 Section 17.2. Solicitation of Holders of Notes.  
 (a) Solicitation. The Company will provide each holder of the Notes (irrespective of the amount of Notes then
owned by it) with sufficient information, sufficiently far in advance of the date a decision is required, to enable such holder to make an informed and considered decision with respect to any proposed amendment, waiver or consent in respect of any
of the provisions hereof or of the Notes. The Company will deliver executed or true and correct copies of each amendment, waiver or consent effected pursuant to the provisions of this Section 17 to each holder of outstanding Notes promptly
following the date on which it is executed and delivered by, or receives the consent or approval of, the requisite holders of Notes. 
 (b) Payment. The Company will not directly or indirectly pay or cause to be paid any remuneration, whether by way of supplemental or additional interest, fee or otherwise, or grant any security, to any holder of
Notes as consideration for or as an inducement to the entering into by any holder of Notes or any waiver or amendment of any of the terms and provisions hereof unless such remuneration is concurrently paid, or security is concurrently granted, on
the same terms, ratably to each holder of Notes then outstanding even if such holder did not consent to such waiver or amendment. 
 (c) Amendment or Waiver in Contemplation of Transfer. Any amendment or waiver made pursuant to this Section 17.2 by a holder of Notes that has transferred or has agreed to transfer its Notes to the Company, any
Subsidiary or any Affiliate of the Company and has provided or has agreed to provide such amendment or waiver as a condition to such transfer shall be void and of no force or effect except solely as to such holder, and any amendments effected or
waivers granted that would not have been or would not be so effected or granted but for such amendment or waiver (and the amendments or waivers of all other holders of Notes that were acquired under the same or similar conditions) shall be void and
of no force or effect, except solely as to such holder. 
 Section 17.3. Binding Effect, etc. Any amendment or
waiver consented to as provided in this Section 17 applies equally to all holders of Notes and is binding upon them and upon each future holder of any Note and upon the Company without regard to whether such Note has been marked to indicate
such amendment or waiver. No such amendment or waiver will extend to or affect any obligation, covenant, agreement, Default or Event of Default not expressly amended or waived or impair any right consequent thereon. No course of dealing between the
Company and the holder of any Note nor any delay in exercising any rights hereunder or under any Note shall operate as a waiver of any rights of any holder of such Note. As used herein, the term “this Agreement” and
references thereto shall mean this Agreement as it may from time to time be amended or supplemented. 
  

 30 

 Exhibit 10(x) (continued) 
  

 Section 17.4. Notes Held by Company, etc. Solely for the purpose of determining whether the holders of the
requisite percentage of the aggregate principal amount of Notes then outstanding approved or consented to any amendment, waiver or consent to be given under this Agreement or the Notes, or have directed the taking of any action provided herein or in
the Notes to be taken upon the direction of the holders of a specified percentage of the aggregate principal amount of Notes then outstanding, Notes directly or indirectly owned by the Company or any of its Affiliates shall be deemed not to be
outstanding. 
 SECTION 18. NOTICES. 
 All notices and communications provided for hereunder shall be in writing and sent (a) by telecopy if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service
(charges prepaid), or (b) by registered or certified mail with return receipt requested (postage prepaid), or (c) by a recognized overnight delivery service (with charges prepaid). Any such notice must be sent: 
 (i) if to you or your nominee, to you or it at the address specified for such communications in Schedule A, or at such other address
as you or it shall have specified to the Company in writing, 
 (ii) if to any other holder of any Note, to such holder at
such address as such other holder shall have specified to the Company in writing, or 
 (iii) if to the Company, to the
Company at its address set forth at the beginning hereof to the attention of Treasury Director, or at such other address as the Company shall have specified to the holder of each Note in writing. 
 Notices under this Section 18 will be deemed given only when actually received. 
 SECTION 19. REPRODUCTION OF DOCUMENTS. 
 This
Agreement and all documents relating thereto, including, without limitation: (a) consents, waivers and modifications that may hereafter be executed, (b) documents received by you at the Closing (except the Notes themselves), and
(c) financial statements, certificates and other information previously or hereafter furnished to you, may be reproduced by you by any photographic, photostatic, microfilm, microcard, miniature photographic or other similar process and you may
destroy any original document so reproduced. The Company agrees and stipulates that, to the extent permitted by applicable law, any such reproduction shall be admissible in evidence as the original itself in any judicial or administrative proceeding
(whether or not the original is in existence and whether or not such reproduction was made by you in the regular course of 

  

 31 

 Exhibit 10(x) (continued) 
  

 
business) and any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence. This Section 19 shall
not prohibit the Company or any other holder of Notes from contesting any such reproduction to the same extent that it could contest the original, or from introducing evidence to demonstrate the inaccuracy of any such reproduction. 
 SECTION 20. CONFIDENTIAL INFORMATION. 
 For the purposes of this Section 20, “Confidential Information” means information delivered to you by or on behalf of the Company or any Subsidiary in connection with the transactions contemplated by or
otherwise pursuant to this Agreement that is proprietary in nature and that was clearly marked or labeled or otherwise adequately identified when received by you as being confidential information of the Company or such Subsidiary (including, without
limitation, any oral information that is specifically identified by the Company to your representatives as “confidential” at the time that such information is received by you), provided that such term does not include information
that (a) was publicly known or otherwise known to you prior to the time of such disclosure, (b) subsequently becomes publicly known through no act or omission by you or any person acting on your behalf, (c) otherwise becomes known to
you other than through disclosure by the Company or any Subsidiary or (d) constitutes financial statements delivered to you under Section 7.1 that are otherwise publicly available. You will maintain the confidentiality of such Confidential
Information in accordance with procedures adopted by you in good faith to protect confidential information of third parties delivered to you and not use (except as contemplated by this Agreement), trade while in possession of, or disclose (to
outside third parties) such Confidential Information, provided that you may deliver or disclose Confidential Information to (i) your directors, officers, employees, agents, attorneys and affiliates (to the extent such disclosure
reasonably relates to the administration of the investment represented by your Notes) and such directors, officers, employees, agents, attorneys and affiliates will be subject to the terms of this Section 20, (ii) your financial advisors
and other professional advisors who agree to hold confidential the Confidential Information substantially in accordance with the terms of this Section 20, (iii) any other holder of any Note, (iv) any Institutional Investor to which
you sell or offer to sell such Note or any part thereof or any participation therein (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 20), (v) any
Person from which you offer to purchase any security of the Company (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 20), (vi) any federal or state
regulatory authority having jurisdiction over you, (vii) the National Association of Insurance Commissioners or, subject to reasonable prior notice and provided such Confidential Information is identified prominently as being confidential, any
similar organization or any nationally recognized rating agency that requires access to information about your investment portfolio, or (viii) subject to reasonable prior notice and provided such Confidential Information is identified
prominently as being confidential, any other Person to which such delivery or disclosure may be necessary or appropriate (w) to effect compliance with any law, rule, regulation or order applicable to you, (x) in response to any subpoena or

  

 32 

 Exhibit 10(x) (continued) 
  

 
other legal process, (y) in connection with any litigation to which you are a party or (z) if an Event of Default has occurred and is continuing,
to the extent you may reasonably determine such delivery and disclosure to be necessary or appropriate in the enforcement or for the protection of the rights and remedies under your Notes and this Agreement. You agree to cooperate with the Company
or any Subsidiary, to the extent the Company or such Subsidiary seeks to object to, or file pleadings or motions with respect to (all objections, pleadings and the like at the sole expense of the Company, including reimbursement to each holder of
the Notes from the Company for any out of pocket costs, fees and/or expenses that such Noteholder may incur as a result of such cooperation), any disclosure pursuant to Clause (vii) (except in the case of the National Association of Insurance
Commissioners) or pursuant to Clause (viii). Each holder of a Note, by its acceptance of a Note, will be deemed to have agreed to be bound by and to be entitled to the benefits of this Section 20 as though it were a party to this Agreement. On
reasonable request by the Company in connection with the delivery to any holder of a Note of information required to be delivered to such holder under this Agreement or requested by such holder (other than a holder that is a party to this Agreement
or its nominee), such holder will enter into an agreement with the Company embodying the provisions of this Section 20. 
 SECTION 21. SUBSTITUTION OF PURCHASER. 
 You shall have the right to
substitute any one of your Affiliates as the purchaser of the Notes that you have agreed to purchase hereunder, by written notice to the Company, which notice shall be signed by both you and such Affiliate, shall contain such Affiliate’s
agreement to be bound by this Agreement and shall contain a confirmation by such Affiliate of the accuracy with respect to it of the representations set forth in Section 6. Upon receipt of such notice, wherever the word “you” is used
in this Agreement (other than in this Section 21), such word shall be deemed to refer to such Affiliate in lieu of you. In the event that such Affiliate is so substituted as a purchaser hereunder and such Affiliate thereafter transfers to you
all of the Notes then held by such Affiliate, upon receipt by the Company of notice of such transfer, wherever the word “you” is used in this Agreement (other than in this Section 21), such word shall no longer be deemed to refer to
such Affiliate, but shall refer to you, and you shall have all the rights of an original holder of the Notes under this Agreement. 
 SECTION 22. MISCELLANEOUS. 
 Section 22.1. Successors and
Assigns. All covenants and other agreements contained in this Agreement by or on behalf of any of the parties hereto bind and inure to the benefit of their respective successors and assigns (including, without limitation, any
subsequent holder of a Note) whether so expressed or not. 
 Section 22.2. Payments Due on Non-Business Days.
Anything in this Agreement or the Notes to the contrary notwithstanding, any payment of principal of or Make-whole Amount or interest on any Note that is due on a date other than a Business Day shall be made on the next succeeding Business Day
without including the additional days elapsed in the computation of the interest payable on such next succeeding Business Day. 
  

 33 

 Exhibit 10(x) (continued) 
  

 Section 22.3. Severability. Any provision of this Agreement that is prohibited or unenforceable in any
jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall (to the
full extent permitted by law) not invalidate or render unenforceable such provision in any other jurisdiction. 
 Section 22.4.
Construction. Each covenant contained herein shall be construed (absent express provision to the contrary) as being independent of each other covenant contained herein, so that compliance with any one covenant shall not (absent such
an express contrary provision) be deemed to excuse compliance with any other covenant. Where any provision herein refers to action to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable whether
such action is taken directly or indirectly by such Person. 
 Section 22.5. Counterparts. This Agreement may be
executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one instrument. Each counterpart may consist of a number of copies hereof, each signed by less than all, but together signed by
all, of the parties hereto. 
 Section 22.6. Governing Law. This Agreement shall be construed and enforced in
accordance with, and the rights of the parties shall be governed by, the law of the State of Illinois excluding choice-of-law principles of the law of such State that would require the application of the laws of a jurisdiction other than such State.

 SIGNATURE PAGE TO FOLLOW 
  

 34 

 Exhibit 10(x) (continued) 
  

 If you are in agreement with the foregoing, please sign the form of agreement on the accompanying counterpart of this Agreement and return it to the
Company, whereupon the foregoing shall become a binding agreement between you and the Company. 
  

			
	Very truly yours,
	  
 SIGMA–ALDRICH CORPORATION

		
	By:	 	/s/ Kirk Richter
	 Name: Kirk Richter
 Title:
Treasurer
  

		
	By:	 	/s/ Karen Miller
	 Name: Karen Miller
 Title:
Controller

 The foregoing is hereby 
 agreed to as of the 
 date thereof. 
 STATE FARM LIFE INSURANCE COMPANY 

			
		
	By:	 	/s/ Lyle Triebwasser
	 Name: Lyle Triebwasser
 Its: Senior
Investment Officer
  

		
	By:	 	/s/ Julie Pierce
	 Name: Julie Pierce
 Its: Investment Officer

 STATE FARM LIFE AND ACCIDENT ASSURANCE COMPANY 

			
		
	By:	 	/s/ Lyle Triebwasser
	 Name: Lyle Triebwasser
 Its: Senior
Investment Officer
  

		
	By:	 	/s/ Julie Pierce
	 Name: Julie Pierce
 Its: Investment Officer

  

 35 

 Exhibit 10(x) (continued) 
  

 INFORMATION RELATING TO PURCHASERS 
 STATE FARM LIFE INSURANCE COMPANY 
 TAX ID #37-0533090 
 Participation Amount: $95,000,000 
 Wire Transfer Instructions: 
 The Chase Manhattan Bank 
 ABA No. 021000021 
 SSG Private Income
Processing 
 A/C #900-9-000200 
 For Credit To Account Number G 06893 
 Ref. PPN # 826552 A* 2 
 Rate: 7.687% 
 Maturity Date:
September 12, 2010 
 Send notices (as well as a photocopy of the original security) to: 
 State Farm Life Insurance Company 
 Investment Dept. E-10 
 One State Farm Plaza 
 Bloomington, IL 61710 
 Send confirms to: 
 State Farm Life Insurance Company 
 Investment Accounting Dept. D-3 
 One State Farm Plaza 
 Bloomington, IL 61710 
 Send the original security (via registered mail) to: 
 Chase Manhattan Bank 
 Attn: Barbara Walsh

 (North America Insurance) 
 3
Chase Metrotech Center-6th Floor 
 Brooklyn, New York 11245 
 Send an additional copy of the original security plus an original set of closing documents and two conformed copies of the Note Purchase Agreement to: 
 State Farm Insurance Companies 
 One State
Farm Plaza E-8 
 Bloomington, Illinois 61710 
 Attn: Investment Legal E-8 
 Larry Rottunda, Investment Counsel 
  

 SCHEDULE A-1 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 STATE FARM LIFE & ACCIDENT ASSURANCE COMPANY 
 TAX ID #37-0805091 
 Participation Amount: $5,000,000 
 Wire Transfer Instructions: 
 The Chase Manhattan Bank

 ABA No. 021000021 
 SSG
Private Income Processing 
 A/C #900-9-000200 
 For Credit To Account Number G 06895 
 Ref. PPN # 826552 A* 2 
 Rate: 7.687% 
 Maturity Date:
September 12, 2010 
 Send notices (as well as a photocopy of the original security) to: 
 State Farm Life and Accident Assurance Company 
 Investment Dept. E-10 
 One State Farm Plaza 
 Bloomington, IL 61710 
 Send confirms to: 
 State Farm Life and Accident Assurance Company 
 Investment Accounting Dept. D-3 
 One State Farm Plaza 
 Bloomington, IL 61710 
 Send the original security (via registered mail) to: 
 Chase Manhattan Bank 
 Attn: Barbara Walsh

 (North America Insurance) 
 3
Chase Metrotech Center-6th Floor 
 Brooklyn, New York 11245 
 Send an additional copy of the original security plus an original set of closing documents and two conformed copies of the Note Purchase Agreement to: 
 State Farm Insurance Companies 
 One State
Farm Plaza E-8 
 Bloomington, Illinois 61710 
 Attn: Investment Legal E-8 
 Larry Rottunda, Investment Counsel 
  

 SCHEDULE A-2 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 DEFINED TERMS 
 As used herein, the following terms have the respective meanings set forth below or set forth in the Section hereof following such term: 
 “Affiliate” means, at any time, and with respect to any Person, any other Person that at such time directly or indirectly through one or more intermediaries Controls, or is Controlled by, or is under common Control with,
such first Person. As used in this definition, “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting
securities, by contract or otherwise. Unless the context otherwise clearly requires, any reference to an “Affiliate” is a reference to an Affiliate of the Company. For purposes of this Agreement, the Purchaser shall not be considered an
Affiliate by virtue of its common stock ownership in the Company. 
 “Book Value” means the applicable property’s
original cost less its accumulated depreciation all in accordance with GAAP. 
 “Business Day” means (a) for the
purposes of Section 8.6 only, any day other than a Saturday, a Sunday or a day on which commercial banks in New York City are required or authorized to be closed, and (b) for the purposes of any other provision of this Agreement, any day
other than a Saturday, a Sunday or a day on which commercial banks in Chicago, Illinois are required or authorized to be closed. 
 “Capital Lease” means, at any time, a lease with respect to which the lessee is required concurrently to recognize the acquisition of an asset and the incurrence of a liability in accordance with GAAP. 
 “Change in Control” means any of the following events or circumstances: (a) if any Person or Persons acting in concert together
with Affiliates thereof, shall in the aggregate, directly or indirectly, control or own (beneficially or otherwise) more than 50% (by number of shares) of the issued and outstanding [voting] stock of the Company.; or (b) if any person (as such
term is used in section 13(d) and section 14(d)(2) of the Exchange Act as in effect on the date of the Closing) or related persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act), become the “beneficial
owners” (as such term is used in Rule 13d-3 under the Exchange Act as in effect on the date of the Closing), directly or indirectly, of more than 50% of the total voting power of all classes then outstanding of the Company’s voting stock.

 “Closing” is defined in Section 3. 
  

 SCHEDULE B-1 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated
thereunder from time to time. 
 “Company” means Sigma-Aldrich Corporation, a Delaware corporation. 
 “Confidential Information” is defined in Section 20. 
 “Consolidated Capitalization” means the sum of Consolidated Indebtedness and Consolidated Net Worth. 
 “Consolidated Indebtedness” means, as of any date of determination, the total of all Indebtedness of the Company and its Subsidiaries outstanding on such date, after eliminating all offsetting debits
and credits between the Company and its Subsidiaries and all other items required to be eliminated in the course of the preparation of consolidated financial statements of the Company and its Subsidiaries in accordance with GAAP. 
 “Consolidated Net Worth” means, at any time: (a) the total assets of the Company and its Subsidiaries which would be shown as
assets on a consolidated balance sheet of the Company and its Subsidiaries as of such time prepared in accordance with GAAP, after eliminating all amounts properly attributable to minority interests, if any, in the stock and surplus of Subsidiaries;
minus (b) the total liabilities of the Company and its Subsidiaries which would be shown as liabilities on a consolidated balance sheet of the Company and its Subsidiaries as of such time prepared in accordance with GAAP; minus
(c) any consolidated balance sheet foreign currency translation adjustment. 
 “Consolidated Total Assets” means the
total assets of the Company and its Subsidiaries which would be shown as assets on a consolidated balance sheet of the Company and its Subsidiaries as of such time prepared in accordance with GAAP, after eliminating all amounts properly attributable
to minority interests, if any, in the stock and surplus of Subsidiaries. 
 “Control Event” means: (a) the execution by
the Company or any of its Subsidiaries or Affiliates of any agreement or letter of intent with respect to any proposed transaction or event or series of transactions or events which, individually or in the aggregate, may reasonably be expected to
result in a Change in Control; or (b) the execution of any written agreement which, when fully performed by the parties thereto, would result in a Change in Control; or (c) the making of any written offer by any person (as such term is
used in section 13(d) and section 14(d)(2) of the Exchange Act as in effect on the date of the Closing) or related persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act as in effect on the date of the Closing) to
the holders of the common stock of the Company, which offer, if accepted by the requisite number of holders, would result in a Change in Control. 
  

 SCHEDULE B-2 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 “Default” means an event or condition the occurrence or existence of which would, with the lapse of time or the giving of
notice or both, become an Event of Default. 
 “Default Rate” means that rate of interest that is the greater of:
(i) 2% per annum above the rate of interest stated in clause (a) of the first paragraph of the Notes or (ii) 2% over the rate of interest publicly announced by Chase Manhattan Bank in New York, New York as its “base” or
“prime” rate. 
 “Environmental Laws” means any and all Federal, state, local, and foreign statutes, laws,
regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into
the environment, including but not limited to those related to hazardous substances or wastes, air emissions and discharges to waste or public systems. 
 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder from time to time in effect. 
 “ERISA Affiliate” means any trade or business (whether or not incorporated) that is treated as a single employer together with the
Company under section 414 of the Code. 
 “Event of Default” is defined in Section 11. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “GAAP” means generally accepted accounting principles as in effect from time to time in the United States of America. 
 “Governmental Authority” means 
 (a) the government of: 
 (i) the United States of America or any State or other political subdivision thereof, or

 (ii) any jurisdiction in which the Company or any Subsidiary conducts all or any part of its business, or which asserts
jurisdiction over any properties of the Company or any Subsidiary, or 
  

 Schedule B-3 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 (b) any entity exercising executive, legislative, judicial, regulatory or administrative functions of, or pertaining to, any such
government. 
 “Guaranty” means, with respect to any Person, any obligation (except the endorsement in the ordinary course
of business of negotiable instruments for deposit or collection) of such Person guaranteeing or in effect guaranteeing any indebtedness, dividend or other obligation of any other Person in any manner, whether directly or indirectly, including
(without limitation) obligations incurred through an agreement, contingent or otherwise, by such Person: 
 (a) to purchase such indebtedness
or obligation or any property constituting security therefor; 
 (b) to advance or supply funds (i) for the purchase or payment of such
indebtedness or obligation, or (ii) to maintain any working capital or other balance sheet condition or any income statement condition of any other Person or otherwise to advance or make available funds for the purchase or payment of such
indebtedness or obligation; 
 (c) to lease properties or to purchase properties or services primarily for the purpose of assuring the owner
of such indebtedness or obligation of the ability of any other Person to make payment of the indebtedness or obligation; or 
 (d) otherwise
to assure the owner of such indebtedness or obligation against loss in respect thereof. 
 In any computation of the indebtedness or other liabilities of the
obligor under any Guaranty, the indebtedness or other obligations that are the subject of such Guaranty shall be assumed to be direct obligations of such obligor. 
 “Holder” means, with respect to any Note, the Person in whose name such Note is registered in the register maintained by the Company pursuant to Section 13.1. 
 “Indebtedness” with respect to any Person means, at any time, without duplication, including both short and long term obligations,

 (a) its liabilities for borrowed money and its redemption obligations in respect of mandatorily redeemable Preferred Stock; 
 (b) its liabilities for the deferred purchase price of property acquired by such Person [excluding: (i) contingent “earn-out” liabilities
relevant to the Company’s 

  

 Schedule B-4 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 
acquisition of First Medical Incorporated, contingent “earn-out” liabilities which are not anticipated (by the Company) to be Material; and
(ii) accounts payable arising in the ordinary course of business but including all liabilities created or arising under any conditional sale or other title retention agreement with respect to any such property]; 
 (c) all liabilities appearing on its balance sheet in accordance with GAAP in respect of Capital Leases; 
 (d) all liabilities for borrowed money secured by any Lien with respect to any property owned by such Person (whether or not it has assumed or otherwise
become liable for such liabilities); 
 (e) all its liabilities in respect of letters of credit or instruments serving a similar function
issued or accepted for its account by banks and other financial institutions (whether or not representing obligations for borrowed money) excluding letters of credit backing up worker’s compensation claims, bid bonds and other similar
obligations (incurred in the Company’s and its Subsidiary’s ordinary course of business which are not, on an accumulated basis, Material; 
 (f) Swaps of such Person, excluding foreign forward currency contracts; and 
 (g) any Guaranty of such Person with respect to
liabilities of a type described in any of clauses (a) through (f) hereof. 
 “Institutional Investor” means
(a) any original purchaser of a Note, (b) any subsequent holder of a Note, and (c) any bank, trust company, savings and loan association or other financial institution, any pension plan, any investment company, any insurance company,
any broker or dealer, or any other similar financial institution or entity, regardless of legal form. 
 “Lien” means, with
respect to any Person, any mortgage, lien, pledge, charge, security interest or other encumbrance, or any interest or title of any vendor, lessor, lender or other secured party to or of such Person under any conditional sale or other title retention
agreement or Capital Lease, upon or with respect to any property or asset of such Person (including in the case of stock, stockholder agreements, voting trust agreements and all similar arrangements). 
 “Make-Whole Amount” is defined in Section 8.6. 
 “Material” means material in relation to the business, operations, affairs, financial condition, assets, or properties of the Company and its Subsidiaries taken as a whole which, on a cumulative
consolidated basis, exceeds 5% of the Company’s Consolidated Total Assets. 
  

 Schedule B-5 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 “Material Adverse Effect” means a material adverse effect on: (i) the financial condition or operations of the
Company and its Subsidiaries taken as a whole; (ii) the ability of the Company to perform its obligations under this Agreement and the Notes; and (iii) the legality, validity or enforceability of this Agreement or the Notes.

 “Multi-employer Plan” means any Plan that is a “multi-employer plan” (as such term is defined in
section 4001(a)(3) of ERISA). 
 “Notes” is defined in Section 1. 
 “Officer’s Certificate” means a certificate of a Senior Financial Officer or of any other officer of the Company whose
responsibilities extend to the subject matter of such certificate. 
 “Other Agreements” is defined in Section 2.

 “Other Purchasers” is defined in Section 2. 
 “PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in ERISA or any successor thereto. 
 “Person” means an individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a
government or agency or political subdivision thereof. 
 “Plan” means an “employee benefit plan” (as defined in
section 3(3) of ERISA) that is or, within the preceding five years, has been established or maintained, or to which contributions are or, within the preceding five years, have been made or required to be made, by the Company or any ERISA
Affiliate or with respect to which the Company or any ERISA Affiliate may have any liability. 
 “Preferred Stock” means any
class of capital stock of a corporation that is preferred over any other class of capital stock of such corporation as to the payment of dividends or the payment of any amount upon liquidation or dissolution of such corporation. 
 “Priority Debt” means, without duplication, the sum of (a) all Indebtedness of the Company secured by any Lien with respect to any
property owned by the Company or any 

  

 Schedule B-6 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 
of its Subsidiaries per Section 10.7(j); and (b) all Indebtedness of Subsidiaries (except Indebtedness owed to the Company or a Subsidiary).

 “property” or “properties” means, unless otherwise specifically limited, real or personal property of
any kind, tangible or intangible, choate or inchoate. 
 “QPAM Exemption” means Prohibited Transaction Class Exemption 84-14
issued by the United States Department of Labor. 
 “Required Holders” means, at any time, the holders of at least 51% in
principal amount of the Notes at the time outstanding (exclusive of Notes then owned by the Company or any of its Affiliates). 
 “Responsible Officer” means any Senior Financial Officer and any other officer of the Company with responsibility for the administration of the relevant portion of this agreement. 
 “Securities Act” means the Securities Act of 1933, as amended from time to time. 
 “Senior Financial Officer” means the chief financial officer, principal accounting officer, treasurer or controller of the Company.

 “Subsidiary” means, as to any Person, any corporation, association or other business entity in which such Person or one
or more of its Subsidiaries or such Person and one or more of its Subsidiaries owns sufficient equity or voting interests to enable it or them (as a group) ordinarily, in the absence of contingencies, to elect a majority of the directors (or Persons
performing similar functions) of such entity, and any partnership or joint venture if more than a 50% interest in the profits or capital thereof is owned by such Person or one or more of its Subsidiaries or such Person and one or more of its
Subsidiaries (unless such partnership can and does ordinarily take major business actions without the prior approval of such Person or one or more of its Subsidiaries). Unless the context otherwise clearly requires, any reference to a
“Subsidiary” is a reference to a Subsidiary of the Company. 
 “Successor Corporation” has the meaning set forth
in Section 10.2 (a) 
 “Swaps” means, with respect to any Person, payment obligations with respect to interest rate
swaps, currency swaps and similar obligations obligating such Person to make payments, whether periodically or upon the happening of a contingency. For the purposes of this Agreement, the amount of the obligation under any Swap shall be the 

  

 Schedule B-7 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 
amount determined in respect thereof as of the end of the then most recently ended fiscal quarter of such Person, based on the assumption that such Swap had
terminated at the end of such fiscal quarter, and in making such determination, if any agreement relating to such Swap provides for the netting of amounts payable by and to such Person thereunder or if any such agreement provides for the
simultaneous payment of amounts by and to such Person, then in each such case, the amount of such obligation shall be the net amount so determined. 
 “Term Sheet” means the summary of terms and conditions of the Financing that was attached to the August 9, 2000 Revised Commitment Letter. 
  

 Schedule B-8 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 EXHIBIT 1 
 FORM OF NOTE 
 SIGMA–ALDRICH CORPORATION 
 7.687% SENIOR NOTE DUE SEPTEMBER 12, 2010 
  

			
	No. ____	  	September 12, 2000
	$            	  	PPN 826552 A* 2

 FOR VALUE
RECEIVED, the undersigned, SIGMA–ALDRICH CORPORATION (herein called the “Company”), a corporation organized and existing under the laws of the State of Delaware, hereby promises to pay to [State Farm Entity] or
registered assigns, the principal sum of One Hundred Million DOLLARS ($100,000,000) on September 12, 2010 with interest (computed on the basis of a 360-day year of twelve 30-day months) (a) on the unpaid balance thereof at
the rate of 7.687% per annum from the date hereof, payable semiannually, on the 12th day of March and September in each year, commencing on
March 12, 2001, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law on any overdue payment (including any overdue prepayment) of principal, any overdue payment of interest and any overdue
payment of any Make-Whole Amount (as defined in the Note Purchase Agreements referred to below), payable semiannually as aforesaid (or, at the option of the registered holder hereof, on demand), at a rate per annum from time to time equal to the
greater of (i) 9.687% or (ii) 2% over the rate of interest publicly announced by Chase Manhattan Bank from time to time in New York, New York as its “base” or “prime” rate. 
 Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at the principal
office of the Company in St. Louis, Missouri or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreements referred to below. 
 This Note is issued pursuant to the Note Purchase Agreement, dated as of September 12, 2000 (as from time to time amended, the “Note Purchase
Agreement”), between the Company and the respective Purchasers named therein and is entitled to the benefits thereof. Each holder of this Note will be deemed, by its acceptance hereof, (i) to have agreed to the confidentiality
provisions set forth in Section 20 of the Note Purchase Agreements and (ii) to have made the representation set forth in Section 6.2 of the Note Purchase Agreements. 
  

 EXHIBIT 1 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 This Note is a registered Note and, as provided in the Note Purchase Agreement, upon surrender of this Note for registration of transfer, duly endorsed, or
accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in the name of, the
transferee. Prior to due presentment for registration of transfer, the Company may treat the person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Company will not
be affected by any notice to the contrary. 
 This Note is subject to optional prepayment, in whole or from time to time in part, at the times and on the
terms specified in the Note Purchase Agreement, but not otherwise. 
 If an Event of Default, as defined in the Note Purchase Agreements, occurs and is
continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreements. 
 This Senior Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the law of the State of Illinois excluding
choice of law principles of the law of such State that would require the application of the laws of a jurisdiction other than such State. 
  

			
	SIGMA–ALDRICH CORPORATION
		
	By:	 	 
	 Name: Kirk Richter
 Title:
Treasurer

  

			
		
	By:	 	 
	 Name: Karen Miller
 Title:
Controller

  

 EXHIBIT 1 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 Schedule 4.9 
 CHANGES IN CORPORATE STRUCTURE 
 Subsequent to December 31, 1999, the
Company completed the acquisitions of ARK Scientific GmbH Biosystems, First Medical, Inc. and Amelung GmbH. Under the terms of the acquisition agreements, the Company assumed certain liabilities of these entities. The liabilities assumed were
primarily accounts payable and other liabilities incurred in the normal course of business by the acquired entities, in each case less than $1,000,000. 
 In
the acquisition of First Medical, Inc. the Company paid at closing an existing loan of First Medical, Inc. of approximately $550,000. 
 In the acquisition
of Amelung GmbH, the Company assumed and, in effect, cancelled a loan of $3,000,000 payable to the Company. 
  

 SCHEDULE 4.9 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 Schedule 5.3 
 DISCLOSURE MATERIALS 
 Discontinued Operations 
 As disclosed in its annual report for the year ending December 31, 1999, the Company announced on November 22, 1999, its strategic decision to seek a buyer for
its B-Line Systems metal business. On March 27, 2000, the Company reached an agreement to sell B-Line Systems to Cooper Industries, Inc. On May 1, 2000, the Company completed the sale to Cooper Industries, Inc. for $425.2 million. The
buyer is reviewing a purchase price adjustment, which is expected to add approximately $6 million to the initial purchase price of $425.2 million. A portion of the funds received from the sale reduced short-term borrowings. Additional funds were
used to continue share repurchase, for acquisitions and other general corporate purposes. 
  

 SCHEDULE 5.3 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 Schedule 5.4 
 Subsidiaries 
 Sigma-Aldrich 
 Corporation 
 Subsidiaries List 
  

							
	 Name of Entity - Principal Place of Business
	  	Description of
Operations	  	State of
Incorporation	  	Inc.
	 Sigma-Aldrich Corporation - St. Louis, MO
	  	Research Chemicals	  	Delaware	  	1975
	 1       Sigma-Aldrich Co. (Illinois)
	  	Research Chemicals	  	Illinois	  	1996
	 (A) Sigma Chemical Company - St. Louis, MO
	  	Research Chemicals	  	Missouri	  	1996
	 (i) Sigma Second Street Redevelopment Corporation
	  	Real Estate Holding	  	Missouri	  	1983
	 (i) Barton/Second Streets Redevelopment Corp.
	  	Real Estate Holding	  	Missouri	  	1988

  

 SCHEDULE 5.4-1 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

									
		  	 (i) Barton Real Estate Holdings, Inc.
	  	Real Estate Holding	  	Missouri	  	1988
		  	 (i) Sigma Redevelopment Corporation
	  	Real Estate Holding	  	Missouri	  	1979
		  	 (i) 3506 South Broadway Redevelopment Corp.
	  	Real Estate Holding	  	Missouri	  	1995
		  	 (i) Second President Properties Company
	  	Research Chemicals	  	Missouri	  	1988
		  	 (i) Midwest Consultants Co. - St. Louis, MO
	  	Research Chemicals	  	Missouri	  	1971
	 *
	  	 (ii) Little Creek Farm, Inc. - Leslie, MO
	  	Dormant/Inactive	  	Missouri	  	1980
	 *
	  	 (i) Sigma F & D Division, Inc.
	  	Dormant/Inactive	  	Missouri	  	1974
	 *
	  	 (i) Sigma-Aldrich Marketing, Inc. - St. Louis, MO
	  	Dormant/Inactive	  	Missouri	  	1990
	 *
	  	 (i) Pathfinder Laboratories Company
	  	Dormant/Inactive	  	Missouri	  	1987
	 *
	  	 (i) Planetary Chemical Inc.
	  	Dormant/Inactive	  	Missouri	  	1951
	 *
	  	 (i) Sigma Pharmaceutical Co.
	  	Dormant/Inactive	  	Missouri	  	1971
		  	 (B) Sigma-Aldrich Chemie Holding GmbH (Germany)
	  	Research Chemicals	  	Germany	  	1985

  

 SCHEDULE 5.4-2 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

									
		  	 (i) Sigma-Aldrich Chemie GmbH (Germany)
	  	Research Chemicals	  	Germany	  	1974
		  	 (ii) Sigma-Aldrich Laborchemikalien GmbH (Germany)
	  	Research Chemicals	  	Germany	  	1997
		  	 (i) Sigma-Aldrich Producktions GmbH (Germany)
	  	Research Chemicals	  	Germany	  	1998
		  	 (i) Amelung (Germany)
	  	Research Chemicals	  	Germany	  	2000
		  	 (i) ARK Scientific GmbH (Germany)
	  	Research Chemicals	  	Germany	  	2000
		  	 (C) Sigma-Aldrich S.r.l.- Milano, Italy
	  	Research Chemicals	  	Italy	  	1987
	 ++
	  	 (D) Sigma-Aldrich Chemie Verwaltungs GmbH - Munich, Germany
	  	Research Chemicals	  	Germany	  	1983
	 ++
	  	 (E) Sigma-Aldrich Grundstucksverwaltung GmbH & Co. K.G. - Munich, Germany
	  	Research Chemicals	  	Germany	  	1974
	 #
	  	 (F) Sigma-Aldrich N.V./S.A. - Bornem, Belgium
	  	Research Chemicals	  	Belgium	  	1984
		  	 (i) Sigma Chemie B.V. (The Netherlands)
	  	Research Chemicals	  	Holland	  	1995

  

 SCHEDULE 5.4-3 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

									
		  	 (G) Sigma-Aldrich Israel, Ltd. - Rehovot, Israel
	  	Research Chemicals	  	Israel	  	1969
		  	 (H) 6Aldrich Chemical Foreign Holding
Company - Milwaukee, WI
	  	Holding Company	  	Missouri	  	1989
		  	 (i) Sigma-Aldrich Chimie S.N.C. Partnership - Cedex, France
	  	Research Chemicals	  	France	  	1989
		  	 (ii) Sigma-Aldrich Chimie S.a.r.l. (France) - Cedex, France
	  	Research Chemicals	  	France	  	1987
		  	 (I) 6Sigma Chemical Foreign Holding
Company (Missouri)
	  	Holding Company	  	Missouri	  	1989
		  	 (J) 1,2 Aldrich Chemical Company, Inc.
- Milwaukee, WI
	  	Research Chemicals	  	Delaware	  	1996
	 *
	  	 (i) GLM Holdings, Inc. - Milwaukee, WI
	  	Dormant/Inactive	  	Wisconsin	  	1991
	 *
	  	 1(i) Aldrich-Boranes,
Inc.
	  	Dormant/Inactive	  		  	1972
		  	 (K) Sigma-Aldrich Business Holdings, Inc.
	  	Real Estate Holding	  	Delaware	  	1996

  

 SCHEDULE 5.4-4 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

									
		  	 (i) Sigma-Aldrich Research Biochemicals, Inc. - Natick, MA
	  		  	Delaware	  	1997
	 *
	  	 (i) Research Biochemicals Limited Partnership
	  	Dormant/Inactive    	  		  	1997
		  	 (L) Sigma-Aldrich Lancaster, Inc.
	  	Research Chemicals	  	Missouri	  	1996
		  	 (i) Carbolabs, Inc. - Bethany, CT
	  	Research Chemicals	  	Conneticut	  	1969
		  	 (i) Techcare Systems, Inc. - Redwood, CA
	  	Research Chemicals	  	California	  	1984
		  	 (ii) MedChem, Ltd. (Russia)
	  	Research Chemicals	  	Russia	  	1997
		  	 (iii) SAFLab (Russia)
	  	Research Chemicals	  	Russia	  	1999
		  	 (ii) TechMed Biochem, Ltd. (Russia)
	  	Research Chemicals	  	Russia	  	1994
		  	 (i) Chemical Trade, Ltd. (Russia)
	  	Research Chemicals	  	Russia	  	1996
		  	 (M) 3,4,5 Sigma-Genosys, Inc -
Woodlands, Texas
	  	Research Chemicals	  	Texas	  	1987
		  	 (N) Sigma Diagnostics, Inc. - St. Louis, MO
	  	Research Chemicals	  	Missouri	  	1996
		  	 (i) First Medical, Inc. (California)
	  		  		  	2000
		  	 (O) Supelco, Inc. - Bellefonte, PA
	  	Chromotography     	  	Delaware	  	1996

  

 SCHEDULE 5.4-5 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

											
		  	*	  	(P) James F. Burns Co., Inc.	  	Dormant/Inactive	  		  	1972
		  	*	  	(Q) KL Acquisition Corp.	  	Dormant/Inactive	  		  	1990
	2	  		  	Sigma-Aldrich Inc. - St. Louis, MO	  	Sales & Marketing	  	Wisconsin	  	1996
		  		  		  	of Chemical
Products	  		  	
	3	  		  	Sigma- Aldrich Finance Co. - Hamilton, Bermuda	  	Holding Company	  	Missouri	  	1996
	4	  		  	Sigma-Aldrich & Subs Foreign Sales Corporation - Barbados	  	FSC	  	Barbados	  	1994
	5	  		  	Sigma-Aldrich Company, Ltd. - Poole, England	  	Research
Chemicals	  	United Kingdom	  	1987
		  	*	  	(A) Sigma- Aldrich Holding, Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1985
		  		  	 (i) Sigma-Genosys Limited (UK)
	  	Research
Chemicals	  	United Kingdom	  	1997
		  	*	  	 (i) Sigma Chemical Company, Ltd. (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1963
		  	*	  	 (ii)Wessex Biochemicals Ltd. (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1963
		  	*	  	 (i) Aldrich Chemical Company, Ltd. (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1959
		  	*	  	 (ii) Webnest, Ltd. (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1973

  

 SCHEDULE 5.4-6 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

											
		  	*	 	 (i) Bristol Organics Ltd. (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1970
		  	*	 	 (i) B-Line Systems Limited (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1990
	 6
	  	**	 	 Fluka Holding AG – Buchs, Switzerland
	  	Holding Compnay	  	Switzerland	  	1950
		  		 	 (A) Fluka Chemie GmbH (Switzerland)
	  	Research Chemicals	  	Switzerland	  	1999
		  		 	 (B) Fluka Production GmbH (Switzerland)
	  	Research Chemicals	  	Switzerland	  	1999
		  		 	 (i) Fluka GmbH (Switzerland)
	  	Holding Company	  	Switzerland	  	1999
		  	*	 	 (C) Fluka Chemical Corp. (Delaware)
	  	Dormant/Inactive	  	Delaware	  	1996
		  	*	 	 (D) Fluka Chemical Company, Ltd. (U.K.)
	  	Dormant/Inactive	  	United Kingdom	  	1967
	 7
	  		 	 Sigma-Aldrich Foreign Holding Company - St. Louis, Missouri
	  	Holding Company	  	Missouri	  	1989
		  		 	 (A) Sigma-Aldrich Handels GmbH - Vienna, Austria
	  	Research Chemicals	  	Austria	  	1993
		  		 	 (B) Sigma-Aldrich de Argentina S.A. - Buenos Aires, Argentina
	  	Research Chemicals	  	Argentina	  	1997
		  	+	 	 (C) Sigma-Aldrich Pty., Limited - N.S.W. 2154, Australia
	  	Research Chemicals	  	Australia	  	1991
		  		 	 (D) Sigma-Aldrich Quimica Brasil Ltda. - Sao Paulo, Brazil
	  	Research Chemicals	  	Brazil	  	1992

  

 SCHEDULE 5.4-7 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

									
	 (E)
	  	 Sigma-Aldrich spol.. s.r.o. - Czech Republic
	  	Research Chemicals	  	Czech Republic	  	1992
	 (F)
	  	 Sigma-Aldrich Canada, Ltd. - Ontario, Canada
	  	Research Chemicals	  	Canada	  	1980
	 (G)
	  	 Sigma-Aldrich Denmark A/S - Denmark
	  	Research Chemicals	  	Denmark	  	1998
	 (H)
	  	 Ya-Kemia Oy - Helsinki, Finland
	  	Research Chemicals	  	Finland	  	1994
	 (I)
	  	 Sigma-Aldrich (OM) Ltd. - Athens, Greece
	  	Research Chemicals	  	Greece	  	1997
	 (J)
	  	 Sigma-Aldrich Kft. - Budapest, Hungary
	  	Research Chemicals	  	Hungry	  	1993
	 (K)
	  	 Sigma-Aldrich India (Bangalore) Branch
	  	Research Chemicals	  	India	  	1992
	 (L)
	  	 Sigma-Aldrich Financial Services Limited - Dublin, Ireland
	  	Holding Company	  	Ireland	  	1998
	 (M)
	  	 Sigma-Aldrich Ireland Ltd.- Dublin, Ireland
	  	Research Chemicals	  	Ireland	  	1997
	 (N)
	  	 Sigma-Aldrich Japan K.K. - Tokyo, Japan
	  	Research Chemicals	  	Japan	  	1994
	 (O)
	  	 Sigma-Aldrich Korea, Ltd. - Seoul, Korea
	  	Research Chemicals	  	Korea	  	1995
	 (P)
	  	 Sigma-Aldrich Quimica, S.A. de C.V. (Mexico)
	  	Research Chemicals	  	Mexico	  	1993
	 (Q)
	  	 Sigma-Aldrich Norway AS - Oslo, Norway
	  	Research Chemicals	  	Norway	  	1996
	 (R)
	  	 Sigma-Aldrich Sp. zo.o - Piznan, Poland
	  	Research Chemicals	  	Poland	  	1994

  

 SCHEDULE 5.4-8 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

									
	 (S)
	  	Sigma-Aldrich Quimica S.A. - Madrid, Spain	  	Research Chemicals	  	Spain	  	1989
		  	(i) Sigma-Aldrich Quimica S.A. (Portugal) Branch	  	Research Chemicals	  	Portugal	  	1998
	 (T)
	  	Sigma-Aldrich Sweden AB - Stockholm, Sweden	  	Research Chemicals	  	Sweden	  	1954
	 (U)
	  	Sigma-Aldrich Pte, Ltd. (Singapore)	  	Singapore	  	Singapore	  	1994
		  	(i) Sigma-Aldrich (M) Sdn. Bhd.- Kuala Lumpur, Malaysia	  	Malaysia	  	Malaysia	  	1997
		  	(i) Sigma-Aldrich Pte. Ltd., (Taiwan) Branch	  	Taiwan	  	Taiwan	  	
	 (V)
	  	Sigma-Aldrich Pty. Ltd. - Midrand, South Africa	  	Research Chemicals	  	South Africa	  	1995

  

 SCHEDULE 5.4-9 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 The above symbols represent the following: 
  

	*	Dormant/Inactive Company 

  

	-	Branch Office 

  

	+	Ownership interest is: 99 shares Sigma-Aldrich Foreign Holding Co.; 1 share Frank Wicks (with agreement requiring the transfer of the share upon termination of employment.)

  

	-	Sigma-Aldrich Company Ltd. (UK) includes the following divisions: Scotland, Sigma, Aldrich, Fluka, Sigma Production and Aldrich Production 

  

	**	Ownership is as follows: Sigma-Aldrich Corporation owns 88.14% and Supelco, Inc. owns 11.86% of Fluka Holding AG 

  

	++	Ownership is as follows: Sigma-Aldrich Co. owns 95% of Sigma-Aldrich Grundstucksverwaltung GmbH & Co. K.G. (formerly Aldrich Chemie GmbH & Co. K.G. ) and
Sigma-Aldrich Chemie Verwaltungs GmbH (formerly Aldrich Chemie Verwaltungs G,bH) owns 5% of Sigma-Aldrich Grundstrcksverwaltung GmbH & Co. K.G. Sigma-Aldrich Co. owns 100% of Sigma-Aldrich Chemie Verwaltungs GmbH. 

 

	-	Sigma-Aldrich Foreign Holding Co. owns all but 1 share by Alfredo Jacobo Sadler (naturalized Argentine citizen; with agreeemnt requiring the transfer of the share upon termination
of employment.) 

  

	#	Belgium law requires 2 shareholders. Sigma-Aldrich Co. owns 1249 shares and Sigma-Aldrich Corporation owns 1 share. 

 Additional Joint Venture and Partnership information. 
  

	1	Aldrich Chemical Company, Inc. and Aldrich-Boranes, Inc. own 59.5% and 0.5% respectively, of AAPL Joint Venture 

  

	2	Aldrich Chemical Compnay, Inc. owns 39.11% of CAMAG Chemie-Erzeugnisse and Adsorptionstechnik AG 

  

	3	Sigma-Genosys, Inc. and Science Tanaka, Ltd. own 50% each of Sigma-Genosys Japan KK Joint Venture 

  

	4	Sigma-Genosys, Inc. and Glen Research Corporation own 50.1% and 49.9% respectively of Genosys Biotin Partners partnership. 

  

	5	Sigma-Genosys, Inc. own s 37.5% of Chemicus, Inc. 

  

	6	Ownership interest in Sigma-Aldrich Chimie SNC partnership (France): Sigma Chemical Foreign Holding Co. 23% and Aldrich Chemical Foreign Holding Co. 77%. 

 

 SCHEDULE 5.4-10 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 SCHEDULE 5.5 
 FINANCIAL STATEMENTS 
 The following Financial Statements are included in and provided with the 1999
Sigma-Aldrich Corporation Annual Report: 
  

			
	Consolidated Statements of Income for the years ended December 31, 1999, 1998 and 1997	  	
	  
 Consolidated Balance Sheets as of December 31, 1999 and
1998
	  	
	  
 Consolidated Statement of Stockholders’ Equity for the years ended
December 31, 1999, 1998 and 1997
	  	
	  
 Consolidated Statements of Cash Flows for the years ended December 31,
1999, 1998 and 1997
	  	

  

 SCHEDULE 5.5 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 SCHEDULE 5.8 
 Certain Litigation 
 None. 
  

 SCHEDULE 5.8 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 SCHEDULE 5.11 
 Patents, Etc. 
 None 
  

 SCHEDULE 5.11 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 SCHEDULE 5.14 
 Use of Proceeds 
 Proceeds of the sale of the Notes are to be used by the Company: 
  

	1)	to reduce short term borrowings; 

  

	2)	to finance future acquisitions; 

  

	3)	to continue share repurchase program; 

  

	4)	to pay income tax liabilities related to the gain on the sale of B-Line Systems; 

  

	5)	for other general corporate purposes. 

  

 SCHEDULE 5.14 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 Schedule 5.15 
 OUTSTANDING INDEBTEDNESS 
 SIGMA-ALDRICH 
 CORPORATION 
 Schedule of Indebtedness 
 As of July 31, 2000 
  

													
	 Payable to
	  	Amount
Outstanding
(in U. S.
Dollars)	  	Currency	  	Interest
Rate	 	 	Date Due	  	Security
	 Firstar Bank, N.A. St. Louis, MO
	  	$	75,501,000	  	USD	  	6.9875	%	 	Revolving
credit
facility	  	Unsecured
	 Bank of Tokyo Mitsubishi Tokyo, Japan
	  	 	4,388,640	  	JPY	  	0.90	%	 	Revolving
credit
facility	  	Unsecured
	 Sanwa Bank Tokyo, Japan
	  	 	3,977,205	  	JPY	  	0.85	%	 	Revolving
credit
facility	  	Unsecured
	 Commerzbank Heidenheim, Germany
	  	 	229,652	  	DM	  			 	2002	  	Warehouse facility
Steinheim,
Germany
	 Bank BPPC Lyon, France
	  	 	248,368	  	FFR	  	5.30	%	 	Bank
overdraft
facility	  	Unsecured
	 ABN - Amro Lyon, France
	  	 	1,006,913	  	FFR	  	4.75	%	 	Bank
overdraft
facility	  	Unsecured
	 Fluka Chemie AG Pension Fund Buchs, Switzerland
	  	 	223,954	  	CHF	  	4.25	%	 	Current
account	  	None

  

 SCHEDULE 5.14 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 Schedule 10.7(f) 
 Existing Liens 
 Mortgage Holder Commerzbank Heidenheim, Germany 
 Mortgaged Property Warehouse, Steinheim, Germany 
 Property Owner Sigma-Aldrich Grundstucksverwaltung
GmbH & Co. K.G. 
 Balance due on Mortgage at July 31, 2000 DM 484,375 
 Payment Schedule DM 96,875 semi-annually 
  

 SCHEDULE 10.7(f) 
 (to Note Purchase Agreement) 

 Exhibit 10(x) (continued) 
  

 FORM OF OPINION OF SPECIAL COUNSEL

 TO THE COMPANY 
 Matters to be Covered in the 
 Opinions of the Special Counsel to the Company 

 1. The Company and each of its Subsidiaries being duly incorporated, validly existing and in good standing and having requisite corporate
power and authority to issue and sell the Notes and to execute and deliver the documents. 
 2. The Company and each of its Subsidiaries
being duly qualified and in good standing as a foreign corporation in appropriate jurisdictions. 
 3. Due authorization and execution of the
documents and such documents being legal, valid, binding and enforceable. 
 4. No conflicts with charter documents, laws or other Material
agreements attached to the applicable Opinion as Schedule A. 
 5. All consents required to issue and sell the Notes and to execute and
deliver the documents having been obtained. 
 6. No litigation questioning validity of documents. 
 7. The Notes not requiring registration under the Securities Act of 1933, as amended; no need to qualify an indenture under the Trust Indenture Act of
1939, as amended. 
 8. No violation of Regulations G, T or X of the Federal Reserve Board. 
 9. Company not an “investment company”, or a company “controlled” by an “investment company”, under the Investment Company
Act of 1940, as amended. 
  

 Exhibit 4.4(a) 
 (to Note Purchase Agreement)Beckman Coulter, Inc. Separation Pay Plan

 Exhibit 10.1 
 BECKMAN COULTER, INC. 
 SEPARATION PAY PLAN 
 BECKMAN INSTRUMENTS, INC. (the “Company”) adopted the Beckman Instruments, Inc. Separation Pay Plan (the “Plan”) as of the 25th day
of October, 1993. The Plan is a welfare benefit plan which is designed to provide payments upon severance to certain employees of the Company and its divisions and subsidiaries. The Plan (including any amendments thereto) is hereby amended and
restated in its entirety effective January 1, 2008, except as otherwise noted below, to comply with Section 409A of the Code and Treasury Regulations and other guidance promulgated thereunder and to make certain other technical amendments
to the Plan. 
 Prior to the adoption of the Plan, the Company maintained a policy of providing notice pay to employees who were scheduled to
be laid off. This Plan replaced any of the policies, plans, or procedures of the Company or its subsidiaries and divisions concerning layoff pay, pay in lieu of notice, or severance pay. 
 WITNESSETH: 
 ARTICLE I. 
 TITLE AND DEFINITIONS 
 1.1 - Title. 

 This Plan shall be known as the “Beckman Coulter, Inc. Separation Pay Plan.” 
 1.2 - Definitions. 
 Whenever the following
terms are used in this Plan, with the first letter capitalized, they shall have the meanings specified below. 
 “Additional
Benefit” shall mean the benefit payable under Section 3.1(b), provided all conditions for eligibility are satisfied. 
 “Administrator” shall mean the Vice President - Human Resources or his or her delegate, as set forth in Article IV. 
 “Anniversary Date” shall mean the date recorded in the Company’s payroll records for purposes of determining an Employee’s vacation accrual rate. The determination of an Employee’s Anniversary Date shall be made by
the Company in its sole and absolute discretion. 
 “Basic Benefit” shall mean the benefit payable under Section 3.1(a),
provided all conditions for eligibility are satisfied. 
  

 1 

 “Code” shall mean the U.S. Internal Revenue Code of 1986, as amended. 
 “Company” shall mean (i) Beckman Coulter, Inc., a Delaware corporation, (ii) any successor corporation resulting from merger,
consolidation, or transfer of assets substantially as a whole, which shall expressly agree in writing to continue the Plan as herein provided, and (iii) unless the context indicates otherwise, any subsidiary of Beckman Coulter, Inc. which, with
the written approval of Beckman Coulter, Inc. elects to participate herein. 
 “Eligible Employee” shall mean an Employee who
becomes eligible for a Separation Pay Benefit in accordance with Section 2.1. 
 “Employee” shall mean any person who is
classified by the Company as a person who renders services to the Company in the status of “employee” as that term is defined in Section 3121(d) of the Code (or its subsequent counterpart), other than any person classified by the
Company as (i) a non-resident alien, or (ii) an intern. 
 “ERISA” shall mean the Employee Retirement Income Security Act
of 1974, as amended from time to time. 
 “Plan” shall mean the Beckman Coulter, Inc. Separation Pay Plan as set forth herein, now
in effect or hereafter amended. 
 “Service” shall mean the period beginning with an Employee’s Anniversary Date and ending
with the Employee’s Severance Date. 
 “Separation from Service” means, as to a particular Employee, a termination of services
provided by the Employee to his or her Employer (as defined below), whether voluntarily or involuntarily, as determined by the Administrator in accordance with Section 409A of the Code and Treasury Regulation Section 1.409A-1(h). In
determining whether an Employee has experienced a Separation from Service, the following provisions shall apply: 
 (i) For an Employee who
provides services to an Employer as an employee, except as otherwise provided in clause (iii) below, a Separation from Service shall occur when the Employee has experienced a termination of employment with the Employer. An Employee shall be
considered to have experienced a termination of employment for this purpose when the facts and circumstances indicate that the Employee and his or her Employer reasonably anticipate that either (A) no further services will be performed by the
Employee for the Employer after the applicable date, or (B) that the level of bona fide services the Employee will perform for the Employer after such date (whether as an employee or as an independent contractor) will permanently decrease to no
more than 20% of the average level of bona fide services performed by the Employee (whether as an employee or an independent contractor) over the immediately preceding 36-month period (or the full period of services to the Employer if the Employee
has been providing services to the Employer less than 36 months). However, if the Employee is on military leave, sick leave, or other bona fide leave of absence, the employment relationship between the Employee and the Employer shall be treated as
continuing intact, provided that the period of such leave does not exceed 6 months, or if longer, so long as the Employee retains a right to reemployment with the Employer under an applicable statute or by contract. If the period of a military
leave, sick leave, or other bona fide leave of absence exceeds 6 months 

  

 2 

 
and the Employee does not retain a right to reemployment under an applicable statute or by contract, the employment relationship shall be considered to be
terminated for purposes of this Plan as of the first day immediately following the end of such 6-month period. In applying the provisions of this paragraph, a leave of absence shall be considered a bona fide leave of absence only if there is a
reasonable expectation that the Employee will return to perform services for the Employer. 
 (ii) For an Employee who provides services to
an Employer as an independent contractor, except as otherwise provided in clause (iii) below, a Separation from Service shall occur upon the expiration of the contract (or in the case of more than one contract, all contracts) under which
services are performed for such Employer, provided that the expiration of such contract(s) is determined by the Administrator to constitute a good-faith and complete termination of the contractual relationship between the Employee and such Employer.

 (iii) For a Employee who provides services to an Employer as both an employee and an independent contractor, a Separation from
Service generally shall not occur until the Employee has ceased providing services for the Employer as both an employee and as an independent contractor, as determined in accordance with the provisions set forth in clauses (i) and
(ii) above. Similarly, if an Employee either (A) ceases providing services for an Employer as an independent contractor and begins providing services for such Employer as an employee, or (ii) ceases providing services for an Employer
as an employee and begins providing services for such Employer as an independent contractor, the Employee will not be considered to have experienced a Separation from Service until the Employee has ceased providing services for such Employer in both
capacities, as determined in accordance with clauses (i) and (ii) above. 
 Notwithstanding the foregoing provisions in this
definition, if an Employee provides services for an Employer as both an employee and as a member of its board of directors, to the extent permitted by Treasury Regulation Section 1.409A-1(h)(5), the services provided by the Employee as a
director shall not be taken into account in determining whether the Employee has experienced a Separation from Service as an employee, and the services provided by such Employee as an employee shall not be taken into account in determining whether
the Employee has experienced a Separation from Service as a director, for purposes of this Plan. 
 For purposes of this definition of
“Separation from Service,” the term “Employer” means the Company or subsidiary of the Company that the Employee last performed services for or was employed by, as applicable, on the date of his or her Separation from Service, and
all other entities that are required to be aggregated together and treated as the employer under Treasury Regulation Section 1.409A-1(h)(3). 
 “Separation Pay Benefit” shall mean the Basic Benefit and, if applicable, the Additional Benefit payable pursuant to Section 3.1. Notwithstanding the foregoing, with respect to an Eligible Executive Employee (as defined in
Appendix C), for purposes of Article III, Separation Pay Benefit shall mean the Executive Benefit described in Appendix C. 
 “Severance
Date” shall mean the date the Eligible Employee incurs a Separation from Service. 
  

 3 

 “Specified Employee” means an Employee who, as of the date of the Employee’s Separation
from Service, is a “specified employee” within the meaning of Treasury Regulation Section 1.409A-1(i). 
 “Weekly Base
Compensation” shall mean the Eligible Employee’s hourly base rate of compensation (including shift premium and shift differential, if any) in effect as of his or her Severance Date times the lesser of (i) forty (40) or
(ii) the number of hours the Eligible Employee was regularly scheduled to work immediately prior to his or her Severance Date. For Employees with a monthly base rate, the hourly base rate is determined by dividing the monthly base rate by
173.33. By way of illustration and not limitation, Weekly Base Compensation shall not include overtime earnings, bonuses or other supplemental compensation. 
 ARTICLE II. 
 ELIGIBILITY 
 2.1 - Eligibility Requirements. 
 (a) An Employee shall be eligible for a
Separation Pay Benefit if he or she is an Employee of the Company, and the Company or its delegate determines that he or she has incurred a Separation from Service as a result of a layoff. Employees covered by a collective bargaining agreement are
not eligible for a Separation Pay Benefit unless eligibility under this Plan has specifically been extended to such Employees through the collective bargaining agreement. 
 (b) No Employee shall be eligible for a Separation Pay Benefit if he or she voluntarily incurs a Separation from Service; provided,
however, that an Employee described in subsection (a) shall be eligible for a Separation Pay Benefit if he or she voluntarily incurs a Separation from Service rather than accept a change in the location of the Employee’s principal
workplace for the Company to a location that is more than fifty (50) miles from the Employee’s principal workplace as of the date immediately preceding the date of such change and that results in an increased commute for the Employee from
his or her principal residence (except for reasonable periods of required travel on Company business); provided, further, that an Employee shall not be eligible for a Separation Pay Benefit under this Section 2.1(b) unless both (x) the
Employee provides written notice to the Company of the condition claimed to satisfy the foregoing relocation provision within ninety (90) days of the initial existence of such condition, and (y) the Company fails to remedy such condition
within thirty (30) days of receiving such written notice thereof; and provided, further, that in all events such voluntary Separation from Service by the Employee must occur not more than one (1) year following the initial existence of
such condition. 
 (c) Notwithstanding the foregoing, an Employee shall not be eligible for a Separation Pay Benefit if
(1) his or her work hours are reduced, as opposed to eliminated; (2) his or her work duties or job title are changed; (3) he or she voluntarily terminates his or her employment with the Company for any reason other than as described
in Section 2.1(b); (4) he or she 

  

 4 

 
terminates his or her employment with the Company as a result of retirement, disability, death, discharge by the Company for cause, or failure to return to
work after an approved leave of absence (including, without limitation, a failure to return for any reason following the expiration of a leave of absence, a failure to return for any reason after a leave of absence ends due to the Employee being
released to return to work, and the failure or inability to return to work because of a medical condition that continues beyond the expiration of the maximum period of a leave of absence); or (5) he or she enters military service. 

(d) Notwithstanding the foregoing, an Employee shall not be eligible for a Separation Pay Benefit if he or she: (1) was employed
on his or her Severance Date as a temporary or contract Employee; or (2) is determined by the Company to be assigned to or otherwise associated with any part of the business of the Company or a subsidiary or division of the Company that was
sold or otherwise transferred to a different company, whether or not the Employee was entitled to retain his or her job with such different company. 
 (e) Notwithstanding the foregoing, an Employee shall not be eligible for a Separation Pay Benefit if he or she is entitled to a payment described in Section 3.1(e) or (f) below. 
 (f) Individuals who are not classified by the Company as employees under Section 3121(d) of the Code (including but not limited to,
individuals classified by the Company as independent contractors and consultants), and individuals who are classified by the Company as employees of an entity other than the Company (or an affiliate of the Company), are not considered
“Employees” under this Plan, even if the classification by the Company is determined to be erroneous. The foregoing sentence sets forth a clarification of the intention of the Company regarding participation in this Plan, and the foregoing
sentence is therefore applicable in interpreting the Plan for any year prior to the addition of this sentence. 
 ARTICLE III.

 BENEFITS PAYABLE UNDER THE PLAN 
 3.1 - Separation Pay Benefit Payable Under the Plan. 
 (a) Basic Benefit. The Basic Benefit
payable to an Eligible Employee shall be determined based on the Eligible Employee’s Service with the Company. Except as otherwise provided, the Basic Benefit shall be an amount equal to the number of weeks of the Eligible Employee’s
Weekly Base Compensation determined according to the following schedule: 
  

			
	 Years of Service
	  	 Basic Benefit

	Less than 3	  	2 weeks
	At least 3, but less than 15	  	1 week per year of Service
	15 or more	  	1-1/2 weeks per year of Service

  

 5 

 Effective for layoffs announced
after March 1, 1998, if after calculating an Eligible Employee’s Basic Benefit, the above schedule results in a Basic Benefit that includes a unit of  1/2 Weekly Base Compensation, such unit shall be rounded up to 3/5 of Weekly Base Compensation. Effective for an Eligible Employee notified of a layoff after December 31, 1999, if after
calculating an Eligible Employee’s Basic Benefit, the above schedule results in a partial week of Basic Benefit, such partial week shall be rounded up to a whole week. 
 Notwithstanding the foregoing, an Eligible Executive Employee (as defined in Appendix C) shall not receive a Basic Benefit. 
 (b) Additional Benefit. In addition to the Basic Benefit, an Eligible Employee shall be eligible for an Additional Benefit if such
Eligible Employee executes and delivers a valid release of all claims against the Company and its agents in a form acceptable to the Company, and the Eligible Employee does not revoke such release within a time period required by law for the
revocation of a release. The Additional Benefit payable to an Eligible Employee shall be determined based on the Eligible Employee’s Service with the Company. Except as set forth below, the Additional Benefit shall be an amount equal to the
number of weeks of the Eligible Employee’s Weekly Base Compensation determined according to the following schedule: 
  

			
	 Years of Service
	  	 Additional Benefit

	Less than 10	  	4 weeks
	At least 10, but less than 15	  	6 weeks
	At least 15, but less than 25	  	8 weeks
	25 and more	  	12 weeks

 Notwithstanding the foregoing, an Eligible Executive Employee (as defined in
Appendix C) shall not receive an Additional Benefit. 
 (c) For purposes of determining an Eligible Employee’s Separation
Pay Benefit under subsections (a) and (b) above, incomplete years of Service shall be rounded up or down to the nearest year. Effective for layoffs or other terminations announced after March 1, 1998, only complete years of Service
shall be regarded for purposes of determining an Eligible Employee’s Service with the Company. In no event shall the Separation Pay Benefit exceed 104 weeks. 
  

 6 

 (d) Notwithstanding the foregoing, the Company may adopt a schedule that provides lower
benefits to a division or location than the benefits set forth in subsections (a) and (b) above. Any such schedule shall be attached hereto as an appendix by an amendment to the Plan and, upon its adoption, shall be considered a part of
this Plan. 
 (e) Any payment of severance benefits under a change in control or similar agreement shall be in lieu of any
Separation Pay Benefit under this Plan. 
 (f) Any payment of severance benefits for international Service under a Company
policy or agreement with an Employee shall be in lieu of any Separation Pay Benefit under this Plan. 
 (g) The Separation Pay
Benefit paid to an Eligible Employee under this Plan shall be reduced by the amount paid to the Eligible Employee under any federal, state or local law which requires a formal notice period, pay in lieu of notice, severance payments or similar
payments. 
 (h) The Separation Pay Benefit shall not be considered “compensation” for purposes of determining any
benefits provided under any pension, savings or other benefit plan maintained by the Company, except as provided specifically herein. 
 3.2 - Payment
of Separation Pay Benefit. 
 (a) Except as otherwise provided in this Plan, the Separation Pay Benefit will be paid
in the form of periodic payments. Subject to Section 3.2(b), payment of the Basic Benefit shall commence as soon as administratively practical following the applicable Severance Date, and payment of the Additional Benefit (if any) shall
commence as soon as administratively practical after the final periodic payment of the Basic Benefit, subject, however, to the Participant’s having executed and delivered to the Company the release contemplated by Section 3.1(b) and not
having revoked such release. The periodic payments shall be paid in accordance with the regular payroll practices in increments (e.g., biweekly) that conform to local practices for similarly situated active Employees. If any laid-off Eligible
Employee is reemployed by the Company or any of its subsidiaries or divisions within the payment period, his or her periodic Basic Benefit payments will cease as of the date such reemployment is effective and, if applicable, any remaining Additional
Benefit payments will continue to be paid according to the same scheduled periodic payment dates. 
 (b) Notwithstanding any
other provision herein, if an Eligible Employee is a Specified Employee as of the date of his or her Separation from Service, the Eligible Employee’s benefits hereunder shall not be paid until the earlier of (i) the date which is six
(6) months after his or her Separation from Service for any reason other than death, or (ii) the date of the Eligible Employee’s death. The provisions of this paragraph shall only apply if, and to the extent, required to avoid the
imputation of any tax, penalty or interest pursuant to Section 409A of the Code. It is the Company’s intent that this Plan will constitute a 

  

 7 

 
“separation pay plan” that provides for benefits only upon an “involuntary separation from service (within the meaning of Section 409A of
the Code and Treasury Regulations promulgated thereunder) and that, accordingly, the six-month waiting period described in this Section 3.2(b) will generally apply to an Eligible Employee’s benefits hereunder only to the extent that such
benefits exceed two (2) times the lesser of (x) the Eligible Employee’s annualized compensation for the year preceding the Eligible Employee’s Severance Date, and (y) the maximum amount that may be taken into account under a
qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Severance Date occurs. Any amounts otherwise payable to an Eligible Employee upon or in the six (6) month period following the Eligible Employee’s
Separation from Service that are not so paid by reason of this Section 3.2(b) shall be paid (without interest) as soon as practicable after the date that is six (6) months after the Eligible Employee’s Separation from Service (or, if
earlier, as soon as practicable after the date of the Eligible Employee’s death). 
 (c) Interest shall not be payable on
any Separation Pay Benefit payment. 
 (d) In the event of an Eligible Employee’s death prior to receiving the full
amount of his or her Separation Pay Benefit, the amount remaining payable under the Plan shall be paid in a lump sum amount to the duly appointed and currently acting personal representative of such Eligible Employee’s estate (which shall
include either the Eligible Employee’s probate estate or living trust). If there is no personal representative of the Eligible Employee’s estate duly appointed and acting in that capacity within 90 days after the Eligible Employee’s
death (or such extended period as the Administrator or delegate thereof determines is reasonably necessary to allow such personal representative to be appointed, but not to exceed 180 days after the Eligible Employee’s death), then such amount
shall be paid in a lump sum amount to the person or persons who can verify by affidavit or court order to the satisfaction of the Administrator or delegate thereof that they are legally entitled to receive the benefits specified hereunder.

 (e) In order for an Eligible Employee to receive payments under this Plan that are exempt from Social Security and Medicare
(FICA) taxes, the Eligible Employee must meet one of the following requirements: 
 (i) He or she must provide the Company
with periodic oral or written confirmation of eligibility for state unemployment benefits; or 
 (ii) He or she must provide
the Company with evidence that he or she would be eligible for state unemployment benefits except for the fact that (A) he or she has insufficient wage credits; (B) he or she has exhausted the duration of state unemployment benefits; or
(C) he or she has failed to satisfy the requisite waiting period, provided that state unemployment benefits will commence once the waiting period expires. 
  

 8 

 3.3 - Inability to Locate Participant. 
 In the event that the Administrator is unable to locate an Eligible Employee within two years following the date the Eligible Employee was to commence
receiving payment of benefits pursuant to this Article III, the Eligible Employee’s entire benefit shall be forfeited. Furthermore, if any benefit payment (by check or other form of payment) to an Eligible Employee remains uncashed or unclaimed
for two years following its delivery to the last known address of the Eligible Employee, the amount of such benefit payment shall be forfeited. Any forfeited amount shall immediately become the property of the Company. If, after such forfeiture, the
Eligible Employee later claims such benefit, such benefit shall be reinstated without interest or earnings. The distribution of such benefits shall thereafter be made in the manner determined by the Administrator. 
 ARTICLE IV. 
 PLAN ADMINISTRATION

 4.1 - Powers and Duties of the Administrator. 
 The Company shall be the plan administrator (as defined in Section 3(16)(A) of ERISA). The Company delegates its duties under the Plan to the Administrator. The Administrator may delegate certain of his or her
duties as provided hereunder to one or more of the Employees of the Company. The Administrator and his or her delegates shall be named fiduciaries of the Plan to the extent required by ERISA. The Administrator shall enforce the Plan in accordance
with its terms, and shall be charged with the general administration of the Plan. In accordance with Section 4.5, the Administrator shall have all powers and duties necessary to accomplish his or her purposes, including but not limited to, the
following: 
 (1) To determine all questions relating to the eligibility of Employees to receive payments hereunder; 
 (2) To construe and interpret the terms and provisions of the Plan; 
 (3) To determine and compute the amount and timing of payments payable to Eligible Employees; 
 (4) To issue
directions to the Company concerning all benefits which are to be paid from the Company’s general assets pursuant to the provisions of the Plan, and warrant that all such directions are in accordance with the Plan; 
 (5) To maintain all the necessary records for the administration of the Plan; 
 (6) To provide for disclosure of all information and filing or provision of all reports and statements to Eligible Employees or governmental bodies as
shall be required by ERISA; 
  

 9 

 (7) To make and publish such rules for the regulation of the Plan as are not inconsistent
with the terms hereof; and 
 (8) To establish claims procedures consistent with regulations of the Secretary of Labor for
presentation of claims by Eligible Employees for Plan benefits, consideration of such claims, review of claim denials and issuance of decisions on review. Such claims procedures at a minimum shall consist of the following: 
 (A) The Administrator or its delegates shall notify Eligible Employees of their right to claim benefits under the claims procedures, may
make forms available for filing such claims, and shall provide the name of the person or persons with whom such claims should be filed. 
 (B) The Administrator or his or her delegates shall establish procedures for action upon claims initially made and the communication of a decision to the claimant promptly and, in any event, not later than ninety
(90) days after the date of the claim, unless special circumstances require an extension for processing the claim. If an extension is required, notice of the extension shall be furnished to the claimant prior to the end of the initial 90-day
period, which notice shall indicate the reasons for the extension and the expected decision date. The extension shall not exceed ninety (90) days. The claim may be deemed by the claimant to have been denied for purposes of further review
described below in the event a decision is not furnished to the claimant within the period described in the preceding three sentences. Every claim for benefits which is denied shall be denied by written notice setting forth in a manner calculated to
be understood by the claimant (1) the specific reason or reasons for the denial, (2) specific references to any provisions of the Plan on which the denial is based, (3) a description of any additional material or information necessary
for the claimant to perfect his claim with an explanation of why such material or information is necessary, and (4) an explanation of the procedure for further reviewing the denial of the claim under the Plan, including a statement of the right
of the claimant to bring an action under Section 502(a) of ERISA following an adverse benefit determination on review. 
 (C) The Administrator shall establish a procedure for review of claim denials, such review to be undertaken by the Administrator. The review given after denial of any claim shall be a full and fair review with the claimant or his duly
authorized representative having sixty (60) days after receipt of denial of his claim to request such review. The claimant shall have the right to submit documents, records, issues, comments and other information in writing which relates to the
claim for benefits, all of which shall be taken into account regardless of whether it was submitted in the initial benefit determination. The claimant shall be provided upon request and at no charge reasonable access to, and copies of, all
documents, records and other information relevant to the claimant’s claim for benefits. The review shall take into account all comments, documents, records and other information submitted by the claimant, regardless of whether such information
was submitted or considered in the initial benefit determination. 
  

 10 

 (D) The Administrator shall establish a procedure for issuance of a decision by the
Administrator not later than sixty (60) days after receipt of a request for review from a claimant unless special circumstances, such as the need to hold a hearing, require an extension of time for processing the claim. If the Administrator
determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant prior to the termination of the initial sixty (60)-day period. The extension notice shall indicate the special
circumstances requiring an extension of time and the date by which the Plan expects to render the determination on review. In no event shall such extension exceed a period of sixty (60) days from the end of the initial period. 
 (E) The Administrator shall provide a claimant with written notice of the Plan’s benefit determination on review. In the case of an
adverse benefit determination, the notification shall set forth, in a manner calculated to be understood by the claimant (1) the specific reason or reasons for the adverse determination; (2) reference to the specific plan provisions on
which the benefit determination is based; (3) a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the
claimant’s claim for benefits; and (4) a statement of the claimant’s right to bring an action under Section 502(a) of ERISA. 
 4.2 -
Transmittal of Information. 
 In order to enable the Administrator to perform his or her functions under the Plan, the Company
shall supply full and timely information to the Administrator on all matters relating to the Weekly Base Compensation of Eligible Employees, their employment, retirement, death, or the cause for termination of employment and such other pertinent
facts as may be required. 
 4.3 - Compensation, Expenses, Indemnity and Liability. 
 (a) The Administrator and his or her delegates shall serve without compensation for their services hereunder. 
 (b) The Administrator is authorized at the expense of the Company to employ such legal counsel, and make use of clerical or other
personnel, as he or she may deem advisable to assist in the performance of his or her duties hereunder. 
  

 11 

 (c) To the extent permitted by applicable law, the Company shall indemnify and save
harmless the Administrator and any Employee of the Company to whom the Administrator has delegated his or her duties under the Plan against any and all expenses, liabilities and claims, including legal fees paid to defend against such liabilities
and claims, arising out of their discharge of responsibilities in good faith under the Plan, excepting only expenses, liabilities and claims arising out of willful misconduct. This indemnity shall not preclude such further indemnities as may be
available under insurance purchased by the Company or provided by the Company under any by-law, agreement, vote of stockholders or disinterested directors or otherwise, as such indemnities are permitted under state law. Payments with respect to the
indemnity and payments of expenses or fees shall be made from the general assets of the Company. 
 4.4 - Manner of Administering. 

The Administrator shall have full discretion to construe and interpret the terms and provisions of the Plan, and shall have full discretion to carry
out his or her other powers and duties. The actions, interpretations or constructions of the Administrator shall be final and binding on all parties, including but not limited to the Company and any Eligible Employee, except as otherwise provided by
law. 
 ARTICLE V. 
 AMENDMENT AND TERMINATION 
 5.1 - Amendments and Termination. 
 The Vice President, Human Resources, of the Company, or any other person whom the Chief Executive Officer of the Company has designated as having the
power to amend the Plan, shall have the power to terminate the Plan and to amend the Plan from time to time and to amend further or cancel any such amendment. Any amendment shall be effective in the manner and at the time therein set forth, and the
Company and all Eligible Employees shall be bound thereby. 
 5.2 - Discontinuance or Termination of Plan. 
 It is the expectation of the Company that the Plan will be continued until all payments are made that may be payable under the Plan, but continuance of
the Plan is not assumed as a contractual obligation of the Company. In the event that the Plan is terminated, no Eligible Employee shall have any claim against any of the assets of the Company. The power to terminate the Plan rests with the officer
or officers of the Company set forth in Section 5.1. 
 ARTICLE VI. 
 MISCELLANEOUS 
 6.1 - Limitation on Eligible Employees’ Rights. 

(a) Payments made under the Plan shall not give any Employee the right to be retained in the Company’s employ or any right or
interest under the Plan other than as herein provided. The Company reserves the right to dismiss any Employee without 

  

 12 

 
any liability for any claim against the Company. Inclusion under the Plan will not give any Eligible Employee any right to claim any benefit hereunder except
to the extent such right has specifically become fixed under the terms of the Plan. An Eligible Employee shall not have any recourse toward satisfaction of such benefit becoming fixed under the terms of the Plan from other than the general assets of
the Company. 
 (b) Payments made under the Plan shall not give any Employee the right to any benefits provided only to
Employees retained in the Company’s employ (e.g., the Company’s health and dental plans). Except as may otherwise be required by law or set forth specifically in such plans, such benefits shall be terminated as of the Employee’s
Severance Date. 
 6.2 - Unsecured General Creditor. 
 All Eligible Employees and their heirs, successors, assigns and personal representatives shall have no legal or equitable rights, claims, or interest in any specific property or assets of the Company with respect to
benefits payable under the Plan. No assets of the Company shall be held under any trust, or held in any way as collateral security for the fulfillment of the obligations of the Company under the Plan. The Company’s assets shall be, and remain,
the general, unpledged, unrestricted assets of the Company. The Company’s obligation under the Plan shall be merely that of an unfunded and unsecured promise of the Company to pay money in the future, and the rights of all Eligible Employees
shall be no greater than those of unsecured general creditors. 
 6.3 - Withholding. 
 There shall be deducted from each payment under the Plan all taxes that are required to be withheld by the Company with respect to such payment. The
Company shall have the right to reduce any payment by the amount of cash sufficient to provide the amount of said taxes. 
 6.4 - Restriction Against
Alienation. 
 None of the benefits, payments, proceeds or claims of any Eligible Employee shall be subject to any claim of any
creditor and, in particular, the same shall not be subject to attachment or garnishment or other legal process by any creditor, nor shall any such Eligible Employee have any right to alienate, anticipate, commute, pledge, encumber or assign any of
the benefits or payments or proceeds which he or she may expect to receive, contingently or otherwise, under the Plan. Notwithstanding the above, benefits which are in pay status may be subject to a court-ordered garnishment or wage assignment, or
similar order, or a tax levy. 
 6.5 - Governing Law. 
 The Plan shall be construed, administered, and governed in all respects under applicable federal law, and to the extent that federal law is inapplicable, under the laws of the State of California; provided, however,
that if any provision is susceptible to more than one interpretation, such interpretation shall be given thereto as is consistent with the Plan being a welfare benefit plan within the meaning of Section 3(1) of ERISA. If any provision of this
instrument shall be held by a court of competent jurisdiction to be invalid or unenforceable, the remaining provisions hereof shall continue to be fully effective. 
  

 13 

 6.6 - Headings, etc., Not Part of Agreement. 
 Headings and subheadings in the Plan are inserted for convenience of reference only and are not to be considered in the construction of the provisions
hereof. 
 6.7 - Instrument in Counterparts. 
 The Plan has been executed in several counterparts, each of which shall be deemed an original, and said counterparts shall constitute but one and the same instrument, which may be sufficiently evidenced by any one
counterpart. 
 6.8 - Reorganization of the Company. 
 In the event of the dissolution, merger, consolidation, or reorganization of the Company, the Plan shall terminate unless the Plan is continued by a successor company in accordance with a resolution of its board of
directors. 
 6.9 - Construction. 
 As used in the Plan, the masculine gender shall include the feminine and the singular may include the plural, unless the context clearly indicates to the contrary. 
 IN WITNESS WHEREOF, the undersigned has caused these presents to be executed by its duly authorized officer on the date indicated below. 
  

			
	BECKMAN COULTER, INC.
		
	By	 	/s/ JAMES ROBERT HURLEY
		 	James Robert Hurley
	Its	 	Senior Vice President Human Resources
	Date 	 	February 20, 2008

  

 14 

 APPENDIX A 
 PARTICIPATION BY AGENCOURT EMPLOYEES 
 Agencourt Biosciences Corporation (“Agencourt”)
shall be a “Company” under the Plan, effective as of May 31, 2005 (the date Agencourt became a wholly-owned subsidiary of the Company). The terms and conditions of the participation of the Agencourt employees shall be
generally-applicable terms and conditions of the Plan, except that for Agencourt employees who were employed by Agencourt as of May 31, 2005, “Service” shall include service with Agencourt prior to May 31, 2005, as recognized and
adjusted on the records of Agencourt for seniority and similar purposes. 
  

 15 

 APPENDIX B 
 Special Rules Related to 2005 Reorganization 
 This Appendix B shall apply to Eligible Employees who
are laid off as part of the Company’s 2005 Reorganization, as well as certain Eligible Employees who voluntarily terminate employment in connection with the Company’s 2005 Reorganization. 
 1. If an Eligible Employee executes, delivers and does not rescind the release specified in Section 3.1(b) of the Plan, the Eligible Employee shall
be eligible for an extension of the ‘Continuing Medical Benefit,’ as defined below. The number of months for which the Continuing Medical Benefit will be extended beyond the number of months specified in Section 3 of this Appendix B
is as follows: 
  

			
	 Years of Service
	  	 Extension of Continuing Medical Benefit

	Less than 15	  	3 Months
	15 to 24	  	6 Months
	25 or more	  	12 Months

 Years of Service shall be determined in accordance with Section 3.1(c) of the Plan.

 2. The Continuing Medical Benefit is the continuation of medical benefit coverage for the Eligible Employee as in effect immediately
before the Eligible Employee’s Severance Date, in exchange for payment by the Eligible Employee of the contribution rate charged to active Employees for such coverage. If the Eligible Employee’s coverage immediately before his or her
Severance Date included coverage for any dependents, the Continuing Medical Benefit shall apply to such dependents’ coverage (subject to payment by the Eligible Employee of the contribution rate charged to active Employees for such
dependents’ coverage). Any changes to the terms of the medical benefit coverage (including changes in the contribution rates) established by the Company for active Employees during the period of the Continuing Medical Benefit shall apply with
respect to the Continuing Medical Benefit. With respect to participants who are eligible for Medicare during their Continuing Medical Benefit period, medical benefits will be paid under the Continuing Medical Benefit as if the participant is also
enrolled in Medicare, even if the participant is not actually enrolled in Medicare. 
 3. Eligible Employees who do not execute and deliver
the release specified in Section 3.1(b) of the Plan, or who rescind such release, shall be entitled (consistent with the Company’s usual policy) to three (3) months of the Continuing Medical Benefit if the Employee has less than 15
years of Service with the Company or six (6) months of the Continuing Medical Benefit if the Employee has 15 or more years of Service with the Company. 
  

 16 

 4. The period of any Continuing Medical Benefit shall cease as of the date the Eligible Employee fails to
pay the required premium, as determined by the Company. 
 5. The expiration of the period of the extension of the Continuing Medical Benefit
shall be deemed the date of the “qualifying event” for continued coverage under ERISA Section 601 et. seq. (commonly called “COBRA”). The period of such COBRA continued coverage (if elected and paid for pursuant to
the Company’s procedures in accordance with the Company’s Welfare Benefits Plan) shall commence upon the expiration of the period of the extension of the Continuing Medical Benefit. If the Eligible Employee is not eligible for the
extension of the Continuing Medical Benefit, then the period described in paragraph 3 above shall count as part of the Eligible Employee’s COBRA continuation coverage period. 
  

 17 

 APPENDIX C 
 Executive Severance Pay Provisions 
 This Appendix C sets forth the eligibility requirements for and
benefits payable under the executive severance pay portion of the Plan (such benefit referred to herein as an “Executive Benefit”). Except to the extent inconsistent with the terms of this Appendix C, all other terms of the Plan shall
remain in full force and effect with respect to Employees who fulfill the requirements of and become entitled to an Executive Benefit under this Appendix C. 
 1. An Employee shall be eligible for an Executive Benefit if such Employee is an Executive Officer, Corporate Vice President or Group Vice President of the Company who incurs a Separation from Service with the Company
at the request of the Board of Directors of Beckman Coulter, Inc. (the “Board”) or, with the support of the Board, the Chief Executive Officer of Beckman Coulter, Inc.; provided, however, that no Employee shall be eligible for an Executive
Benefit if such Employee’s service with the Company is terminated for cause. Without limiting the powers and authority of administration under Article IV, all determinations of eligibility for an Executive Benefit shall be determined by the
Administrator, except that any determination as to whether the Administrator (in his capacity as an executive of the Company) is eligible for an Executive Benefit shall be made by the Company’s Chief Executive Officer. 
 2. The Executive Benefit payable to an Employee meeting the requirements of Section 1 of this Appendix C (an “Eligible Executive
Employee”) shall be determined based on the Eligible Executive Employee’s Service with the Company. The Executive Benefit shall be equal to the product of (i) the number of the Eligible Executive Employee’s full years of Service
with the Company and (ii) two (2) times the Eligible Executive Employee’s monthly base rate of compensation; provided, however, that the Executive Benefit shall in no event be less than six (6) times the Eligible Executive
Employee’s monthly base rate of compensation, and shall in no event be more than eighteen (18) times the Eligible Executive Employee’s monthly base rate of compensation. Notwithstanding the foregoing sentence, the Executive Benefit in
the case of the Chief Executive Officer of the Company (the “CEO”) shall be equal to the product of (x) the number of the CEO’s full years of Service with the Company and (y) three (3) times the CEO’s monthly base
rate of compensation; provided, however, that the CEO’s Executive Benefit shall in no event be less than nine (9) times the CEO’s monthly base rate of compensation, and shall in no event be more than twenty-four (24) times the
CEO’s monthly base rate of compensation. Payment of the Executive Benefit is in lieu of the Basic Benefit and the Additional Benefit otherwise payable under the Plan. 
 3. An Eligible Executive Employee shall be entitled to an Executive Benefit only if the Eligible Executive Employee executes, delivers, does not revoke
and complies with all of the Eligible Executive Employee’s obligations under (i) a general release of claims against the Company and its agents, and (ii) to the extent requested by the Company, an agreement not to compete with the
Company, its subsidiaries and its affiliates and/or not to solicit the employees or customers of the Company, its subsidiaries and its affiliates (the “Release and Noncompetition Agreement”). The Release and Noncompetition Agreement shall
be in a form acceptable to the 

  

 18 

 
Company. Notwithstanding anything in the Plan to the contrary, if an Eligible Executive Employee revokes or fails to execute and deliver the Release and
Noncompetition Agreement in accordance with the preceding two sentences, such Eligible Executive Employee shall receive no benefits under this Plan. Furthermore, if an Eligible Executive Employee fails to comply with all of the Eligible Executive
Employee’s obligations under the Release and Noncompetition Agreement (including, for example, by engaging in competition with the Company), (i) the release of claims against the Company shall continue to apply, (ii) the Eligible
Executive Employee shall not be entitled to payment of any benefits under this Plan that had not been paid as of the date the Eligible Executive Employee first failed to comply with any of such obligations, and (iii) the Company shall be
entitled to recoup any benefits under this Plan that were paid after the date the Eligible Executive Employee first failed to comply with any of such obligations. 
 4. Payment of the Executive Benefit shall be made in accordance with Section 3.2. 
  

 19 

 APPENDIX D 
 PARTICIPATION BY DAKO COLORADO EMPLOYEES AND 
 SPECIAL TRANSITIONARY RULES 
 1. Participation by Dako Colorado Employees. Dako Colorado, Inc. (“Dako”) shall be a “Company” under the Plan immediately upon
the Company’s acquisition of Dako. The terms and conditions of the participation of Dako employees shall be the generally-applicable terms and conditions of the Plan, except as set forth in this Appendix D. For Dako employees who were employed
by Dako as of the date of the Company’s acquisition of Dako, “Service” shall include service with Dako prior to such acquisition date, as recognized and adjusted on the records of Dako for seniority and similar purposes. 

2. Special Transition Rule for Initial Dako Participants. Notwithstanding Section 1 of this Appendix D, for individuals who were employees
of Dako as of the date of the Company’s acquisition of Dako and who become entitled to benefits under the Plan as a result of a layoff by the Company that occurs on or before December 31, 2009, (i) the Separation Pay Benefit shall, in
lieu of any other Separation Pay Benefit under the Plan and not in addition thereto, be equal to two weeks of Weekly Base Compensation for each year of Service, and (ii) such Separation Pay Benefit shall only be payable if such individual
executes and delivers a valid release of all claims against the Company and its agents in a form acceptable to the Company, and such individual does not revoke such release within a time period required by law for the revocation of a release.

 3. Special Transition Rule. A Dako employee is (and at the time of the Company’s acquisition of Dako, was) subject to a
written agreement expressly setting forth such employee’s entitlement to separation pay benefits in the event such employee becomes entitled to benefits as a result of a layoff that occurs on or before April 29, 2008. Accordingly, and
notwithstanding Section 1 of this Appendix D, if such employee becomes entitled to benefits under the Plan as a result of a layoff by the Company that occurs on or before April 29, 2008, (i) the Separation Pay Benefit shall, in lieu
of any other Separation Pay Benefit under the Plan and not in addition thereto, be 17.33 weeks of Weekly Base Compensation (regardless of such employee’s Service), and (ii) such Separation Pay Benefit shall only be payable if such employee
executes and delivers a valid release of all claims against the Company and its agents in a form acceptable to the Company, and does not revoke such release within a time period required by law for the revocation of a release. 
 4. Employees Entitled to Dako Denmark Benefits not Eligible. Notwithstanding Section 1 of this Appendix D, any employee who, as determined by
the Company, is eligible (or could become eligible by applying) for a severance or similar benefit payable by Dako Denmark or for which Dako Denmark retained or assumed any liability in connection with the Company’s acquisition of Dako, shall
not participate in this Plan and shall not be entitled to any benefits under this Plan. 
  

 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]